---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description. Covers Product description and Place of product in therapy. 395 evidence topics quoted from 153 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary

Mineralys Therapeutics submitted a New Drug Application (NDA) for lorundrostat to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”. The FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. The company described the application as still under review in its third quarter 2026 results announcement and in its release on the Transform-HTN results presented on November 8, 2026. According to the company, the NDA includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial; the Explore-OSA trial was not part of the original application. In its 2026 Form 10-Q, the company described an advisory committee meeting as “not anticipated currently”. No FDA expedited program designation and no marketing application outside the United States was found. The company has stated no launch date; it describes its commercial preparations as on track for “launch upon approval”. In its third quarter 2025 results announcement, the company had planned the submission for “near the end of 2025 or during the first quarter of 2026”.

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for); [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026); [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026

> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

> “Based on the positive results from our pivotal program, we submitted an NDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### Commercial launch preparation: launch planned upon approval, no date stated

> “As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval,”
> “The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “While the FDA continues its review of the NDA, our focus is on completing our launch preparations so that we are ready to reach patients soon after the potential approval of lorundrostat.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

> “We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension,”

Source: [Mineralys Therapeutics press release, board appointments (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/122/mineralys-therapeutics-expands-its-board-of-directors-with)

> “PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval”
> “The Company expects to have the sales organization established in advance of the anticipated PDUFA target date.”

Source: [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026)

<a id="topic-2.1.1-5"></a>

##### FDA acceptance of the NDA, March 2026

> “announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-2.1.1-6"></a>

##### NDA submission, December 2025

> “Mineralys filed an NDA for lorundrostat to the U.S. Food and Drug Administration (FDA) in late 2025.”

Source: [Mineralys Therapeutics press release, corporate update (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and)

> “We also ended the year with the submission of our first NDA for the treatment of hypertension in adults.”

Source: [Mineralys Therapeutics fourth quarter 2025 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/94/mineralys-therapeutics-reports-fourth-quarter-2025)

<a id="topic-2.1.1-7"></a>

##### Trials included in the NDA

> “The NDA includes the positive data from the LAUNCH-HTN and ADVANCE-HTN pivotal trials, as well as the proof-of-concept trial EXPLORER-CKD and our open-label extension trial TRANSFORM-HTN.”
> “EXPLORER-OSA was not part of the original NDA application.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

> “The NDA submission included the diverse dataset the Company has built with lorundrostat across five positive clinical trials that demonstrated clinically meaningful blood pressure (BP) reduction, 24-hour control and a favorable safety profile in adults with uncontrolled or resistant hypertension.”
> “The Company’s ongoing open-label extension trial, which supported the NDA submission, enables participants to continue to receive lorundrostat and allows the Company to gather additional long-term safety and efficacy data.”

Source: [Mineralys Therapeutics first quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/100/mineralys-therapeutics-reports-first-quarter-2026-financial)

> “Ahead of the NDA submission in December 2025, we completed five successful clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN or rHTN. This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial,”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.1-8"></a>

##### Advisory committee meeting: not anticipated

> “conducting ongoing regulatory activities, including responding to FDA information requests, supporting a potential advisory committee meeting (not anticipated currently), preparing for potential approval and post-marketing commitments, and potential commercial launch of lorundrostat;”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.1-9"></a>

##### FDA expedited program designations (Fast Track, Breakthrough Therapy, Priority Review)

No evidence found.

<a id="topic-2.1.1-10"></a>

##### Marketing applications outside the United States

No evidence found.

<a id="topic-2.1.1-11"></a>

##### NDA submission planned for late 2025 or the first quarter of 2026, November 2025, superseded in December 2025

> “Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026”
> “These findings for lorundrostat will provide the foundation for an NDA submission which we anticipate submitting near the end of 2025 or during the first quarter of 2026,”

Source: [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-12"></a>

##### Pre-NDA feedback from the FDA, October 2025

> “We are at an exciting point in our company’s history as we prepare for our NDA submission following pre-NDA feedback from the FDA last month.”

Source: [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-13"></a>

##### Pivotal Launch-HTN and Advance-HTN topline results, March 2025

> “today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-2.1.1-14"></a>

##### Phase 2 Target-HTN topline results, November 2022

> “today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension.”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-2.1.1-15"></a>

##### First-in-human study by Tanabe, November 2016 to May 2017

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “lorundrostatum” |
| International nonproprietary name (English) | “lorundrostat” |
| Functional description | “aldosterone synthase inhibitor” |
| Molecular formula | “C24H33N7O2” |
| CAS registry number | “1820940-17-7” |

Source: [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)

> “N-(trans-4-acetamidocyclohexyl)-2-{4-[5-(4-”
> “methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-”

Source: [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)

<a id="topic-2.1.2.1-2"></a>

###### Development codes: MLS-101 and MT-4129

> “A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

> “A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

> “pursuant to which Tanabe granted the Company an exclusive, worldwide, royalty-bearing, sublicensable license under Tanabe’s patent and other intellectual property rights to exploit products incorporating lorundrostat (formerly MT-4129) (Lorundrostat Product)”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Manufacturer: Mineralys Therapeutics

> “Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.1-5"></a>

###### Originator and license: Tanabe Pharma Corporation

> “We licensed lorundrostat from Tanabe Pharma Corporation (Tanabe), which discovered the compound and provided the early foundational work, including demonstrating the selectivity of lorundrostat, and progressing the asset through Phase 1 clinical development.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “On June 2, 2026, the Company entered into a fourth amendment to the Tanabe License (the Fourth Amendment), pursuant to which the Company’s obligation to pay Tanabe royalties on net sales of Lorundrostat Products was terminated, the license was amended and restated to grant the Company an exclusive, worldwide, royalty-free, sublicensable, perpetual, irrevocable license,”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

> “Tanabe has also agreed to subsequently assign to Mineralys its intellectual property rights related to lorundrostat.”

Source: [Mineralys Therapeutics press release, Tanabe royalty repurchase (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/104/mineralys-therapeutics-announces-repurchase-of-royalty)

| Field | Quoted record |
| --- | --- |
| Lead sponsor of the first-in-human study | “Tanabe Pharma Corporation” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class: oral, highly selective aldosterone synthase inhibitor

> “Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational dosage form: oral tablet

> “The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6.”
> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Tablet, administered orally”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

> “Lorundrostat tablet.”
> “Lorundrostat matching placebo tablet.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-2.1.2.2-2"></a>

###### Doses studied in phase 2 and phase 3 trials: 12.5 mg to 100 mg

> “The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “Participants were assigned to one of three groups: placebo; lorundrostat 50 mg once daily; or lorundrostat 50 mg once daily with the option to increase to 100 mg at week six.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

> “The open-label starting lorundrostat dose was 50 mg once daily, or 25 mg if the previously blinded treatment dose was reduced.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “This trial was designed to evaluate blood pressure reduction and safety of 25 mg once-daily lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

<a id="topic-2.1.2.2-3"></a>

###### First-in-human formulation: capsule

> “single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.2-4"></a>

###### Commercial strengths and package sizes

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Wholesale acquisition cost and average sales price of lorundrostat

No evidence found.

<a id="topic-2.1.2.3-2"></a>

###### Lorundrostat price not finalized or disclosed, November 2026

> “As we've stated in the past, pricing is something that we'll communicate as well as our thoughts on access and gross to net sometime post approval, post launch.”
> “Part of that is price, part of that is the rebate strategy and part of it is what Eric described as the patient support program.”
> “Obviously, we haven't finalized the price yet, so that hasn't been revealed to the payer, but anticipate once we have approval, a relatively quick engagement and to start turning over some of that access in very short term.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.3-3"></a>

###### Company pricing frame: branded SGLT2 inhibitor and Entresto price points, March 2026

> “We have talked in the past, Annabel, that as a guidance or a frame for pricing, we have always directed to probably more of an SGLT2-branded price point, Entresto price point, broadly at a WAC, but have not guided as it relates to rebates.”
> “I think we continue to feel very strong about the value proposition of lorundrostat, the need specifically in the resistant hypertension population, and so we believe that both the combination of appropriate price and rebate is going to create that access.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.3-4"></a>

###### Price and reimbursement as competitive factors

> “If we successfully obtain approval for lorundrostat or any future product candidate, we believe that the key competitive factors that will affect the success of lorundrostat will be efficacy, safety, tolerability, convenience, price, and the availability of reimbursement from government and other third-party payors relative to such competing products.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.3-5"></a>

###### ICER placeholder price for lorundrostat: baxdrostat wholesale acquisition cost, October 2026

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets).”
> “For lorundrostat, we used the baxdrostat WAC price as a placeholder price.”
> “At lorundrostat’s annual placeholder price of $10,950, the cumulative annual budget impact per patient was approximately $8,500 in year one and $16,300 by year five.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.3-6"></a>

###### ICER health benefit price benchmark for lorundrostat, October 2026

> “The HBPB for baxdrostat is $1,400 to $2,500 per year and for lorundrostat is $760 to $1,600 per year.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO INN functional description: aldosterone synthase inhibitor

> “aldosterone synthase inhibitor”

Source: [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)

<a id="topic-2.1.2.4-3"></a>

###### Class of the first FDA-approved aldosterone synthase inhibitor, baxdrostat

> “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication: treatment of hypertension in combination with other antihypertensive drugs

> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

###### Indication wording in the NDA acceptance announcement: adult patients

> “the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-2.1.2.5-3"></a>

###### Target population named by the company: uncontrolled or resistant hypertension

> “Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.2.5-4"></a>

###### Population of the pivotal trials: blood pressure uncontrolled on two to five antihypertensive medications

> “Launch-HTN (NCT06153693) was a global, randomized Phase 3 double-blind, placebo-controlled trial of adults whose blood pressure (BP) remained uncontrolled despite being on two to five antihypertensive medications.”
> “Advance-HTN (NCT05769608) was a randomized, double-blind, placebo-controlled Phase 2 clinical trial that evaluated the efficacy and safety of lorundrostat for the treatment of uncontrolled or resistant hypertension, when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications in adult participants.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-2.1.2.5-5"></a>

###### Intended line of therapy: third line or later

> “We believe the Launch-HTN and Advance-HTN trial results demonstrate the opportunity for lorundrostat in third-line or later treatment of patients with hypertension.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “I think it is going to be, as I noted, a beachhead at fourth line. That is clearly where there is unmet need. That is clearly where the value resonates. With experience and demand, I think that begins to open up third line.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

> “Our expectation is that certainly at the beginning, it will likely be in that fourth line resistant hypertension.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Selective inhibition of aldosterone synthase (CYP11B2)

> “Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective ASI designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.”
> “The approach of blocking the synthesis of aldosterone and reducing plasma aldosterone levels is thought to be a preferable approach versus the use of MRAs that block the action of aldosterone at the MR.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “Lorundrostat is a novel molecular entity (Figure 1) designed to target the renin–angiotensin–aldosterone system (RAAS), via inhibition of aldosterone synthase (CYP11B2) resulting in targeted suppression of aldosterone production.”
> “Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 (CYP) enzyme that converts 11‐deoxycorticosterone (11‐DOC) to aldosterone in three consecutive steps”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.1-2"></a>

###### In vitro potency and selectivity over 11β-hydroxylase (CYP11B1)

> “Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).”
> “CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.”
> “Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “Lorundrostat is highly selective for aldosterone and shows no cortisol suppression and no incidence of adrenal insufficiency, as anticipated by the 374-to-1 inhibitory effect on the CYP11B2 enzyme compared to the CYP11B1 enzyme, which is responsible for synthesizing cortisol.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Reduction of circulating aldosterone compared with mineralocorticoid receptor antagonists

> “In contrast to mineralocorticoid receptor antagonists (MRAs), lorundrostat is designed to reduce rather than stimulating the substantial increase in circulating aldosterone seen with MRAs.”
> “This unique difference is anticipated to reduce adverse non‐MR‐mediated aldosterone signaling via the GPER (GPR30) receptor on blood vessels and other tissues, avoiding the estrogenic side effects of MRAs”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “Additionally, when aldosterone is blocked from binding to the MR, circulating aldosterone levels increase two- to three-fold and may cause other harmful non-MR-related effects in the body.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Plasma aldosterone suppression after single and multiple doses in healthy participants

> “Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).”
> “PAC (AUC0–24) was reduced by up to 40% with single 100‐ to 200‐mg doses and up to 70% with single 400‐ to 800‐mg doses.”
> “At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose.”
> “Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-2"></a>

###### Aldosterone rebound after discontinuation in healthy participants

> “From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.”
> “From Day 7 to Day 9, clear reductions in the urinary log10 (10 × Na+/K+) ratio were observed, suggesting a rebound effect for the sodium/potassium ratio as well.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-3"></a>

###### Basal and cosyntropin-stimulated cortisol in healthy participants

> “During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-4"></a>

###### Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants

> “Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.”
> “Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).”
> “Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.”
> “Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-5"></a>

###### Aldosterone reduction in participants with hypertension: company summary

> “Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.2.6.2-6"></a>

###### Serum aldosterone, plasma renin activity, and cortisol in uncontrolled hypertension: Target-HTN

> “Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.”
> “Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.6.2-7"></a>

###### Serum aldosterone and plasma renin activity in hypertension with chronic kidney disease: Explore-CKD

> “The geometric mean serum aldosterone level decreased by 41.5% during treatment with lorundrostat and increased by 1.8% during placebo treatment. The geometric mean plasma renin activity increased by 75.2% with lorundrostat and 4.2% with placebo. The geometric mean aldosterone-to-renin ratio decreased by 67.2% during treatment with lorundrostat and by 5.8% with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.6.2-8"></a>

###### Aldosterone, plasma renin activity, and aldosterone-renin ratio through week 48: Transform-HTN

| Biomarker | Percent change in geometric mean from Launch-HTN baseline at week 48 |
| --- | --- |
| Serum aldosterone | “-54.8%” |
| Plasma renin activity | “+123.9%” |
| Aldosterone-renin ratio | “-79.8%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### Circulating heart failure risk biomarkers: post hoc proteomic analysis of Launch-HTN and Advance-HTN

> “The PD analysis confirmed that lorundrostat was associated with significant increases in renin and decreases in angiotensinogen, reflecting target engagement of the renin-angiotensin-aldosterone system (RAAS). Lorundrostat was associated with significant reductions in 6 of 11 recently published candidate causal risk biomarkers of incident HF, including NT-proBNP, consistent with the hypothesis that RAAS inhibition favorably modulates processes involved in HF risk.”
> “This analysis characterized the systemic pharmacodynamic (PD) effects of lorundrostat and generated hypotheses regarding its potential modulation of pathways implicated in HF pathophysiology by profiling circulating protein biomarkers at baseline and after 12 weeks from 1,004 participants enrolled in the pivotal Phase 3 Launch-HTN and Phase 2b Advance-HTN trials.”

Source: [Mineralys Therapeutics press release, ENDO 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/108/mineralys-therapeutics-presents-late-breaking-data-on)

<a id="topic-2.1.2.6.2-10"></a>

###### Cardiac repolarization: concentration-QTc analysis in healthy participants

> “On the basis of this analysis, an effect on placebo-corrected ΔQTcF (ΔΔQTcF) >10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~7800 ng/mL”
> “On the basis of the MAD results, an effect on ΔΔQTcF exceeding 10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~6175 ng/mL”
> “There were no participants in the SAD and MAD studies with QTcF >450 ms or ΔQTcF >30 ms”
> “On the basis of these data, the regulatory requirement for a thorough QT study was waived”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.6.2-11"></a>

###### Cardiac ion channel and nonclinical cardiovascular safety

> “Lorundrostat was a weak inhibitor of hERG (mean [SEM] inhibition of 6.9% [2.5%] at 10 µM) with a half-maximal inhibitory concentration (IC50) of 95.4 µmol/L”
> “There were no statistically significant differences in blood pressure, QRS duration, QT interval, or QTc for lorundrostat up to 100 mg/kg versus placebo at any of the assessed time points”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption, half-life, and clearance after single doses in healthy participants

> “Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.”
> “The interindividual variability of exposure parameters (C max and AUC0–∞) were low to moderate (<20%).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-2"></a>

###### Dose proportionality

> “Over the dose range of 5–800 mg of lorundrostat in part 1, dose proportional increases in systemic exposure in terms of AUC0–∞ were observed as the 95% CIs of the slopes for the AUCs vs. dose included the value 1.”
> “In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).”
> “In addition, systemic exposure in terms of the AUC0–24 and C max appeared to increase in a slightly more than dose proportional manner over the tested multiple‐dose range on Days 1 and 7 (Figure S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-3"></a>

###### Steady state and accumulation with once-daily dosing

> “A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.”
> “After single‐ and multiple‐dose lorundrostat administration, plasma levels peaked 1–3 h after administration with a t 1/2 of 10–12 h.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “The half-life of lorundrostat (10-12 hours) is ideally suited for once-daily dosing.”
> “Lorundrostat’s observed 10 to 12 hour half-life may be viewed more favorably by physicians compared to compounds with longer half-lives, which may have a greater risk of sustained potassium elevation.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.6.3-4"></a>

###### Renal excretion of unchanged drug

> “After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%. The fraction of the lorundrostat dose excreted remained consistent over the dose range tested. Renal clearance (CLR) was low and generally similar across dose levels (mean CLR ranging between 0.3–0.5 L/h) after a single dose on Day 1.”
> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-5"></a>

###### Food effect

> “Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.”
> “Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-6"></a>

###### Relative exposure of the capsule and tablet formulations

> “The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-7"></a>

###### Predicted peak concentration at 100 mg once daily

> “This concentration is 4.8-fold higher than the predicted maximum observed plasma concentration (Cmax) at the maximum clinically efficacious dosage of 100 mg once daily”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Metabolism, protein binding, and volume of distribution

No evidence found.

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Adverse events of special interest: Launch-HTN

> “Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.”
> “The prespecified adverse events of hyponatremia, hyperkalemia, and reduction in kidney function (decline in eGFR) were reported more with lorundrostat compared with placebo; however, few treatment discontinuations occurred due to these events.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

| Event, No. (%) | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 538) | Placebo (n = 270) |
| --- | --- | --- | --- |
| Serious adverse event | “2 (0.7)” | “12 (2.2)” | “8 (3.0)” |
| Hypotension with symptoms | “5 (1.9)” | “11 (2.0)” | “1 (0.4)” |
| Hyperkalemia requiring modification of trial drug | “7 (2.6)” | “11 (2.0)” | “1 (0.4)” |
| Hyponatremia requiring modification of trial drug | “28 (10.4)” | “37 (6.9)” | “9 (3.3)” |
| Reduction in estimated glomerular filtration rate requiring modification of trial drug | “9 (3.3)” | “16 (3.0)” | “2 (0.7)” |
| Glucocorticoid deficiency confirmed by stimulation test | “0” | “0” | “3 (1.1)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.7.1-3"></a>

###### Hyperkalemia: Launch-HTN

> “A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo”
> “The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 1.1% and 1.5% in the 50 mg and 50 to 100 mg arms, respectively.”
> “The per-protocol procedure for validation of suspected factitious hyperkalemia (most often due to phlebotomy-related hemolysis and release of potassium from red blood cells) specified a repeat potassium measurement within 72 hours while still taking study medication to confirm validity and provide an accurate determination of the true incidence of hyperkalemia.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 0.6% and 1.1% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-4"></a>

###### Hyperkalemia: Advance-HTN

> “A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 5.3% and 7.4% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 2.1% and 3.2% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-5"></a>

###### Hyperkalemia: Target-HTN

> “Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial”
> “No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.”
> “Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.7.1-6"></a>

###### Hyperkalemia: Explore-CKD

> “Hyperkalemia occurred more frequently with lorundrostat than with placebo (15.5% vs 3.5%), with 5.2% of lorundrostat-treated participants experiencing a confirmed serum potassium concentration >6.0 mmol/l.”
> “Per protocol modification of the study drug dose due to hyperkalemia and reduction in kidney function were the most common AEs of special interest, occurring in 8.6% (n = 5) and 10.3% (n = 6) of participants during lorundrostat treatment, respectively, versus none with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-7"></a>

###### Hyperkalemia: Explore-OSA

> “Lorundrostat demonstrated a favorable safety profile and was well tolerated, with no serum potassium excursions above 5.5 mmol/L.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

###### Hyperkalemia: company summary across trials

> “A majority of our clinical trial participants maintained a serum potassium in the normal range. There have been modest incidences of hyperkalemia requiring dose adjustment or discontinuation.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-9"></a>

###### Adverse events during 36 weeks of open-label treatment: Transform-HTN

| Event | Lorundrostat (N=632), n (%) |
| --- | --- |
| Any serious adverse event | “27 (4.3)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Hyperkalemia requiring modification of trial drug | “32 (5.1)” |
| Hyponatremia requiring modification of trial drug | “28 (4.4)” |
| Hypotension with symptoms | “13 (2.1)” |
| Serum potassium >6.0 mmol/L confirmed by repeat testing | “16 (2.5)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Consistent with lorundrostat’s mechanism of action, serum potassium increased and eGFR decreased early in treatment; both remained stable through the open-label period to Week 48.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.7.1-10"></a>

###### Hyponatremia

> “Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “No serum sodium values <125 mmol/l occurred”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-11"></a>

###### Adverse events in Advance-HTN

| Event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Any serious adverse event | “2%” | “6%” | “8%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), confirmed by repeat testing | “0” | “2%” | “3%” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “A dose escalation strategy from 50 to 100 mg did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “In the Advance-HTN trial, there were six participants (6.4%) and eight participants (8.4%) with treatment-emergent SAEs in the lorundrostat 50 mg and lorundrostat 50 to 100 mg arms, respectively, compared to two participants (2.1%) in the placebo arm.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-12"></a>

###### Decline in estimated glomerular filtration rate

> “Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.”
> “An acute, reversible decline in eGFR of similar or greater magnitude has also been observed with renin-angiotensin-aldosterone system inhibitors and sodium glucose cotransporter inhibitors”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “Nine participants experienced an eGFR (cystatin C) decrease ≥25%. There were no eGFR decreases ≥50%”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

> “During the lorundrostat treatment period, an anticipated, modest decrease in mean eGFR was observed (-6.8% lorundrostat, -4.6% mL/min/1.73m2 placebo-adjusted). Reduction in eGFR is also seen with other renin-angiotensin-aldosterone pathway inhibitors, including ACE inhibitors, ARBs, and MRAs.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “An early drop in eGFR was observed, as expected, after which eGFR remained stable within each study”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-2.1.2.7.1-13"></a>

###### Symptomatic hypotension

> “Prespecified adverse events of special interest included 3 participants (2%) with hypotension.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.7.1-14"></a>

###### Adrenal insufficiency and cortisol

> “The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group.”
> “There were no reports of hyperadrenocorticism.”
> “At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “No clinically meaningful changes in serum cortisol were observed in either treatment sequence.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-15"></a>

###### Adverse events in healthy participants: first-in-human study

> “Lorundrostat was well tolerated and no serious TEAEs occurred during the study.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).”
> “None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.7.1-16"></a>

###### Company risk factors: adverse effects and labeling

> “Use of lorundrostat or any future product candidates could be associated with adverse side effects, adverse events, or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label, or result in other significant negative consequences”
> “Undesirable side effects caused by our product candidates when used alone or in combination with approved or investigational drugs could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label, or lead to the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-17"></a>

###### Class context: warnings and precautions for the approved aldosterone synthase inhibitor baxdrostat

> “BAXFENDY can cause hyperkalemia”
> “Assess serum potassium prior to initiation of BAXFENDY and monitor periodically during treatment.”
> “More frequent monitoring is recommended for patients at increased risk of hyperkalemia (e.g., patients ≥ 65 years of age, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium)”
> “Permanently discontinue BAXFENDY if clinically significant hyperkalemia recurs.”
> “BAXFENDY can cause hyponatremia”
> “Assess serum sodium prior to initiation of BAXFENDY and monitor periodically during treatment.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Older adults: pharmacokinetics in healthy men aged 65 years or older

> “In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4). The median T max value was earlier for older adult participants (1.0 h) vs. younger adult participants (1.5 h), and the mean t 1/2 value was slightly longer for older adult (11.4 h) than for younger adult (10.0 h) participants.”
> “In parts 3 and 4, the change from baseline of PAC and serum cortisol concentrations at 24 h after a single 100‐mg dose of lorundrostat was similar in male and female participants, as well as in those aged 18–55 years and aged ≥65 years.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-2"></a>

###### Sex: pharmacokinetics in healthy women

> “In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4). The median T max values were comparable for female participants (1.3 h) and male participants (1.5 h), and the mean t 1/2 value was slightly longer for females (12.4 h) than for males (10.0 h).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-3"></a>

###### Age, sex, race, and body mass index: Launch-HTN subgroups

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

| Subgroup | Lorundrostat 50 mg, change in AOSBP at week 6 (mmHg) | Placebo, change in AOSBP at week 6 (mmHg) | Difference (90% CI) |
| --- | --- | --- | --- |
| Age ≥75 years | “-18.2” | “-6.6” | “-11.6 (-17.4, -5.8); p=0.0011” |
| Age 65 to 74 years | “-16.7” | “-9.8” | “-6.9 (-11.4, -2.4); p=0.0109” |
| Age <65 years | “-16.9” | “-7.6” | “-9.3 (-13.2, -5.4); p<0.0001” |
| Black or African American | “-15.1” | “-8.3” | “-6.7 (-11.6, -1.9); p<0.0222” |
| White | “-17.1” | “-8.0” | “-9.2 (-12.8, -5.6); p<0.0001” |
| Female | “-16.8” | “-7.4” | “-9.4 (-13.6, -5.3); p=0.0002” |
| Male | “-17.0” | “-8.2” | “-8.8 (-12.6, -5.1); p<0.0001” |
| BMI ≥30 kg/m2 | “-16.5” | “-6.9” | “-9.6 (-13.3, -5.8); p<0.0001” |
| BMI <30 kg/m2 | “-17.9” | “-9.5” | “-8.4 (-12.6, -4.3); p=0.0009” |

Source: [Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase)

> “Launch-HTN is the largest global Phase 3 trial to date in uncontrolled or resistant hypertension, enrolling a diverse group of participants with high cardiovascular risk, including Black/African American (29%), adults aged ≥65 years (41%), women (47%), participants with obesity (63%), and those requiring three or more background antihypertensive medications (60%).”

Source: [Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase)

<a id="topic-2.1.2.8-4"></a>

###### Race and ethnicity: first-in-human study population

> “All participants were white and none were of Hispanic or Latino ethnicity.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-5"></a>

###### Obesity: Target-HTN and Advance-HTN

> “Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Key secondary end point | Result |
| --- | --- |
| Relationship of BMI to blood pressure reduction at 4 weeks | “No clear relationship” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Renal impairment: low urinary excretion of unchanged drug

> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-7"></a>

###### Renal impairment: eGFR thresholds for enrollment

> “The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Key exclusion criteria were serum potassium >5.0 mmol/l, serum sodium <135 mmol/l, eGFR <30 ml/min per 1.73 m2, and uncontrolled diabetes (glycated hemoglobin >10%).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.8-8"></a>

###### Chronic kidney disease stages 1 to 3: Launch-HTN analysis

> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table).”
> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants. In LOR 50mg participants, mean cystatin C-based eGFR decreased by 7.3, 4.0 and 4.2 mL/min/1.73 m2 in those with CKD stage 1, 2, and 3, respectively, compared with 2.1 mL/min/1.73 m2 in those without CKD.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.1.2.8-9"></a>

###### Chronic kidney disease with albuminuria: Explore-CKD

> “At baseline, mean automated office systolic blood pressure (AOSBP) was 149 mmHg, UACR (urinary albumin-to-creatinine ratio, an indicator of kidney protein loss) was 516.8 mg/g and mean estimated glomerular filtration rate (eGFR) was 43 mL/min/1.73m2 based on cystatin C.”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

> “In this study, hyperkalemia was the principal safety finding in participants with CKD and was the most common investigator-reported TEAE during the 4-week treatment period.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.8-10"></a>

###### Hepatic impairment

No evidence found.

<a id="topic-2.1.2.8-11"></a>

###### Hepatic disease: exclusion from the first-in-human study

> “Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal, neurological, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-2.1.2.8-12"></a>

###### Pregnancy and lactation: exclusion from the trials

> “Women who are pregnant, plan to become pregnant, or are breastfeeding”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

> “Fertile male subjects and female subjects of childbearing potential, and their partners, must agree to use an acceptable method of contraception from study entry to 28 days after the last dose of study drug”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

> “healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive)”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-13"></a>

###### Pediatric population

> “At least 18 years of age at the time of signing the informed consent form (ICF)”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lorundrostat

<a id="topic-2.1.2.9.1-1"></a>

###### Strong CYP3A4 inhibitors: predicted exposure

> “is also higher than the high clinical exposure scenario when lorundrostat is given with strong CYP3A4 inhibitors (~1.2-fold increase in Cmax)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Mineralocorticoid receptor antagonists, potassium-sparing diuretics, and epithelial sodium channel inhibitors: prohibited in the trials

> “The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.9.1-3"></a>

###### Background renin-angiotensin system inhibitors and SGLT2 inhibitors: serum potassium and eGFR

> “were placed on a standardized antihypertensive regimen that included a high-dose angiotensin receptor blocker prior to randomization; greater increases in serum potassium level and decreases in eGFR were observed compared with those in the current trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Hyperkalemic events occurred in participants receiving background ACEi/ARB and SGLT2i therapy.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.9.1-4"></a>

###### Clinical drug-drug interaction studies

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lorundrostat on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### MATE1-dependent transport: competition with creatinine

> “The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Cystatin-C formula, a surrogate biomarker of renal function not subject to MATE1 transport and elimination in the glomeruli of the kidney.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.9.2-2"></a>

###### Clinical drug-drug interaction studies

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Launch-HTN: 50 mg once daily, with escalation to 100 mg at week 6 in one group

> “participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).”
> “Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.”
> “The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.”
> “Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.10.1-2"></a>

###### Advance-HTN: 50 mg once daily, or 50 mg increased to 100 mg after 4 weeks

> “participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-2.1.2.10.1-3"></a>

###### Target-HTN: dose-ranging from 12.5 mg once daily to 100 mg once daily

> “Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).”
> “randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.”
> “The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.10.1-4"></a>

###### Transform-HTN: 50 mg once daily, or 25 mg after a dose reduction

> “The open-label starting lorundrostat dose was 50 mg once daily, or 25 mg if the previously blinded treatment dose was reduced.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.10.1-5"></a>

###### Explore-CKD: 25 mg once daily

> “4-week treatment with oral lorundrostat 25 mg once daily”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.10.1-6"></a>

###### Explore-OSA: 50 mg once daily in the evening

> “evaluated the safety and efficacy of lorundrostat 50 mg QD administered in the evening in 48 participants with hypertension and moderate-to-severe OSA”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.10.1-7"></a>

###### Doses evaluated in healthy participants

> “The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg”
> “The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.10.1-8"></a>

###### Proposed labeled dose

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral tablets once daily in the morning: Launch-HTN

> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.”
> “Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6.”
> “Participants were reminded about taking their trial medication using a smartphone application (AiCure).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration with or without food

> “Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.10.2-3"></a>

###### Evening administration: Explore-OSA

> “After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the AHI, the primary endpoint.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.10.2-4"></a>

###### Once-daily compared with twice-daily dosing

> “This suggests that allowing an overnight period of escape from aldosterone suppression may have safety benefits when compared with aldosterone synthase inhibitors or aldosterone receptor blockers with longer half-lives, including spironolactone, which has active metabolites with half-lives exceeding 24 hours.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial launch readiness: sales force, medical affairs, and brand preparation, November 2026

> “The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place. The Company continues to engage with leading hypertension experts and payers. Brand marketing preparations are well underway, and the Company is finalizing a full-service patient support program designed to ease access for physicians, their office staff and patients.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “From an execution standpoint, I am pleased to report that our field sales team is now in place. In addition to our seasoned commercial leadership team, we have hired sales representatives with an average industry tenure of approximately 15 years.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-2"></a>

###### Payer engagement before approval

> “On the market access front, our engagement with payers now extends to the majority of U.S. covered lives. Our discussions continue to center on the clinical and economic burden of uncontrolled hypertension and the value proposition supported by lorundrostat's clinical data package.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

> “An experienced commercial leadership team is now in place, initial sales territories and priority geographies have been identified, and engagement continues with leading hypertension experts and payers covering a substantial majority of U.S. lives.”

Source: [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026)

> “The team was engaging Medicare as well as commercial payers. I will say we are on their radar. They are very well aligned with the positioning that John spoke of, and we are now in the midst of scheduling these pre-approval information exchange, or PIE, discussions.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.11-3"></a>

###### Anticipated coverage at launch: commercial plans first, Medicare through the exception process

> “So from a payer coverage perspective, Rami, so definitely commercial will lead the way in terms of providing that access or that coverage initially. But we will, and we do anticipate Medicare coverage through the exception process, as I mentioned on a prior response. The Medicare exception process typically looks at the label, but it does require some navigation of that in which the PSP that we put forward is designed to support that.”
> “We've gotten questions in the past about missing the bid cycle as AstraZeneca did. Presuming we get approved, we won't hit that bid cycle as well, whether or not patients on Medicare will get access.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-4"></a>

###### Patient support program

> “In parallel, we are finalizing a full-service patient support program designed to help physicians, their office staff and patients navigate access efficiently.”
> “In terms of timing, so shortly after launch, you can anticipate that patient support program.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-5"></a>

###### Target prescribers: about 60,000 physicians, 60% primary care and 40% specialty

> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”
> “It is about a 60/40 split, primary care/specialty, the bulk of the specialty being cardiologists.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.11-6"></a>

###### Manufacturing by third-party contract manufacturers

> “We do not own or operate manufacturing facilities for the production of lorundrostat, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for our required raw materials, active pharmaceutical ingredients, and finished product candidates for our clinical trials.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or limited distribution network

No evidence found.

<a id="topic-2.1.2.11-8"></a>

###### Sales, marketing, and distribution strategy not yet defined, March 2026, superseded in August 2026

> “We have not yet defined our sales, marketing, or product distribution strategy for lorundrostat because it is still in clinical development and pending regulatory approval. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or the establishment of our own commercial sales force.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Proposed use in combination with other antihypertensive drugs

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.12-2"></a>

###### Launch-HTN: background regimen of 2 to 5 prescribed antihypertensive medications

> “Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.”
> “Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-3"></a>

###### Launch-HTN: background drug classes and other medications at randomization, No. (%)

| Medication | Lorundrostat 50 mg and then 100 mg (n = 270) | Lorundrostat 50 mg (n = 541) | Placebo (n = 272) |
| --- | --- | --- | --- |
| Taking 2 antihypertensive medications | “106 (39.3)” | “213 (39.4)” | “113 (41.5)” |
| Taking ≥3 antihypertensive medications | “164 (60.7)” | “328 (60.6)” | “159 (58.5)” |
| Thiazide or thiazide-like diuretic | “259 (95.9)” | “520 (96.1)” | “259 (95.2)” |
| ACE inhibitor or ARB | “237 (87.8)” | “467 (86.3)” | “225 (82.7)” |
| Calcium channel blocker | “140 (51.9)” | “278 (51.4)” | “135 (49.6)” |
| Glucagon-like peptide-1 receptor agonists | “13 (4.8)” | “30 (5.6)” | “9 (3.3)” |
| Sodium-glucose cotransporter 2 inhibitors | “14 (5.2)” | “21 (3.9)” | “13 (4.8)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-4"></a>

###### Launch-HTN: prohibited concomitant drugs

> “The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-5"></a>

###### Advance-HTN: standardized background regimen of an ARB and a diuretic, with or without a calcium channel blocker

> “Participants who met screening criteria had their existing hypertension medications discontinued and started on a standard regimen of an angiotensin II receptor blocker (ARB) and a diuretic, if previously on two medications, or a standard regimen of ARB, diuretic and calcium channel blocker if previously on three to five medications.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

> “In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-2.1.2.12-6"></a>

###### Target-HTN: background therapy and excluded concomitant drugs

> “Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.”
> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA,”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.12-7"></a>

###### Target-HTN: larger blood pressure reduction with a background thiazide diuretic, November 2022

> “A prespecified sub-analysis demonstrated that blood pressure reduction by MLS-101 was further enhanced in subjects whose background antihypertensive regimen included a thiazide diuretic:”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-2.1.2.12-8"></a>

###### Explore-CKD: added to an ACE inhibitor or ARB and an SGLT2 inhibitor

> “This trial was designed to evaluate blood pressure reduction and safety of 25 mg once-daily lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor for the treatment of hypertension in participants with CKD with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 and albuminuria (UACR of 200-5,000 mg/g).”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

> “Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-2.1.2.12-9"></a>

###### Transform-HTN: existing antihypertensive medications continued

> “These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications.”
> “Results were similar among participants taking two background antihypertensive medications and those taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lorundrostat on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### HEDIS Controlling High Blood Pressure (CBP)

> “The percentage of persons 18–85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement period.”

Source: [NCQA Controlling High Blood Pressure measure](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/controlling-high-blood-pressure-cbp/)

<a id="topic-2.1.2.13-2"></a>

###### HEDIS Blood Pressure Control for Patients With Hypertension (BPC-E)

> “The percentage of persons 18–85 years of age who had a diagnosis of hypertension (HTN) and whose most recent blood pressure (BP) was <140/90 mm Hg during the measurement period.”

Source: [NCQA Blood Pressure Control for Patients With Hypertension measure](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/blood-pressure-control-for-patients-with-hypertension-bpc-e/)

<a id="topic-2.1.2.13-3"></a>

###### Medicare Part C Star Ratings: Controlling Blood Pressure (C14)

> “Percent of plan members with high blood pressure who got treatment and were able to maintain a healthy pressure.”
> “The percentage of MA members 18–85 years of age who had a diagnosis of hypertension (HTN) (denominator) and whose blood pressure (BP) was adequately controlled (less than 140/90 mm Hg) (numerator).”

Source: [CMS 2027 Part C and D Star Ratings Technical Notes (2026)](https://www.cms.gov/files/document/2027-tech-notes-2026-09-30.pdf)

<a id="topic-2.1.2.13-4"></a>

###### Medicare Part D Star Ratings: Medication Adherence for Hypertension (RAS antagonists) (D09)

> “The percentage of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are taking the medication.”
> “This measure is defined as the percentage of Medicare Part D beneficiaries, 18 years and older, who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists: ACE inhibitor, ARB, or direct renin inhibitor medications.”

Source: [CMS 2027 Part C and D Star Ratings Technical Notes (2026)](https://www.cms.gov/files/document/2027-tech-notes-2026-09-30.pdf)

<a id="topic-2.1.2.13-5"></a>

###### Medicare Star Ratings weights of the blood pressure measures, 2027

| Measure | Weighting category | Weight |
| --- | --- | --- |
| “Controlling Blood Pressure” | “Intermediate Outcome Measure” | “3” |
| “Medication Adherence for Hypertension (RAS antagonists)” | “Intermediate Outcome Measure” | “3” |

Source: [CMS 2027 Star Ratings Measures and Weights (2026)](https://www.cms.gov/files/document/2027-star-ratings-measures.pdf)

<a id="topic-2.1.2.13-6"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: lorundrostat and the add-on options for uncontrolled hypertension

- Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
- Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
- Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
- Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.

Source: [FDA NDA 219878 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf); [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf); [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf); [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf); [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf); [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023); [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Tsou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13587145/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Lorundrostat: Launch-HTN primary endpoint, for comparison with the add-on drugs below

> “For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.14-3"></a>

###### Baxdrostat (BAXFENDY, AstraZeneca): FDA approval, May 2026

> “This NDA provides for the use of Baxfendy (baxdrostat) tablets for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
> “It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”
> “05/15/2026”

Source: [FDA NDA 219878 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf)

> “AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.”

Source: [AstraZeneca press release, BAXFENDY US approval (2026)](https://www.businesswire.com/news/home/20260518258445/en/)

<a id="topic-2.1.2.14-4"></a>

###### Baxdrostat (BAXFENDY): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.” |
| Recommended dosage | “The recommended dosage of BAXFENDY is 2 mg orally once daily.” |
| Dosage at increased risk of hyperkalemia or hyponatremia | “For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily” |
| Strengths | “Tablets: 1 mg and 2 mg” |
| Contraindications | “None.” |
| Warnings and precautions | “Hyperkalemia: Assess serum potassium before initiation and periodically thereafter.” |
| Warnings and precautions | “Hyponatremia: Assess serum sodium before initiation and periodically thereafter.” |
| Most common adverse reaction | “The most common adverse reaction (more frequent than placebo and ≥ 5% in BAXFENDY-treated patients) was hyperkalemia.” |
| Drug interactions | “Strong and moderate CYP3A inducers: Monitor the therapeutic effect of BAXFENDY more frequently during concomitant use.” |
| Renal impairment | “Safety and effectiveness of BAXFENDY initiated in patients with eGFR < 45 mL/min/1.73 m2 have not been established” |
| Elimination half-life | “The mean effective half-life of baxdrostat was approximately 26 hours (range 23 to 32 hours).” |
| Cardiovascular outcomes | “There are no controlled trials demonstrating risk reduction of these events with BAXFENDY.” |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Baxdrostat: BaxHTN primary endpoint in the prescribing information, seated systolic blood pressure at week 12

| Systolic blood pressure (mmHg) | BAXFENDY 2 mg | BAXFENDY 1 mg | Placebo |
| --- | --- | --- | --- |
| Participants | “n=266” | “n=264” | “n=263” |
| Baseline (mean) | “149.1” | “149.7” | “149.0” |
| Change from baseline (mean) | “-15.7” | “-14.5” | “-5.8” |
| Difference from placebo (95% CI) | “-9.8 (-12.6, -7.0)” | “-8.7 (-11.5, -5.8)” | |
| p-value vs. placebo | “< 0.0001” | “< 0.0001” | |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “The primary endpoints were change from baseline to Week 12 in seated office systolic blood pressure for BAXFENDY 2 mg once daily compared to placebo and for BAXFENDY 1 mg once daily compared to placebo.”
> “The change in mean systolic blood pressure during the 8-week randomized withdrawal period was -3.7 mmHg (95% CI -5.5, -1.9) in the BAXFENDY 2 mg arm and +1.4 mmHg (95% CI -1.2, 4.0) in the placebo arm, for a mean difference from placebo of -5.1 mmHg (95% CI -8.3, -1.9; p-value 0.002).”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Baxdrostat: BaxHTN publication

> “794 participants were randomized to and received baxdrostat 1mg (n=264), baxdrostat 2mg (n=266), or placebo (n=264) in addition to background therapy.”
> “Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively. Potassium >6.0 mmol/l occurred in 6 participants (2.3%) with baxdrostat 1mg, 8 (3.0%) with baxdrostat 2mg, and 1 (0.4%) with placebo.”

Source: [Flack et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618089/)

<a id="topic-2.1.2.14-7"></a>

###### Baxdrostat: Bax24 trial, 24-hour ambulatory systolic blood pressure in resistant hypertension

> “At 12 weeks, the change from baseline in the least-squares mean 24 h ambulatory SBP was -16·6 mm Hg (95% CI -18·8 to -14·3) in the baxdrostat group (n=89) and -2·6 mm Hg (-4·7 to -0·4) in the placebo group (n=95); the estimated placebo-corrected difference was -14·0 mm Hg (-17·2 to -10·8; p<0·0001).”
> “A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-2.1.2.14-8"></a>

###### Baxdrostat: adverse reactions in the pooled 12-week placebo-controlled periods

| Adverse reaction | BAXFENDY 2 mg (N=441), % | BAXFENDY 1 mg (N=333), % | Placebo (N=442), % |
| --- | --- | --- | --- |
| Hyperkalemia | “10.2” | “6.6” | “2.5” |
| Hypotension | “3.6” | “2.1” | “0.5” |
| Hyponatremia | “3.2” | “2.1” | “0.9” |
| Dizziness | “2.9” | “3.0” | “0.9” |
| Muscle spasms | “2.9” | “1.8” | “0.7” |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “Hyperkalemia led to permanent discontinuation of treatment in 8 (1.8%) patients in the BAXFENDY 2 mg group, 2 (0.6%) patients in the BAXFENDY 1 mg group, and none in the placebo group.”
> “At Week 12, the mean placebo-corrected decrease in eGFR was 8.0 mL/min/1.73 m2 in the BAXFENDY 2 mg group and 7.1 mL/min/1.73 m2 in the BAXFENDY 1 mg group.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Baxdrostat: CHMP positive opinion in the European Union, November 2026

> “AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products.”
> “Baxfendy is approved in the US and other countries as a first-in-class ASI for adults with hypertension not adequately controlled on other therapies, with regulatory filings currently under review in other major regions, including Japan and China.”

Source: [AstraZeneca press release, Baxfendy EU CHMP opinion (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html)

<a id="topic-2.1.2.14-10"></a>

###### Baxdrostat: anticipated FDA action date, December 2025, superseded by approval in May 2026

> “The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 2026 following use of a Priority Review voucher.”

Source: [AstraZeneca press release, baxdrostat NDA acceptance (2025)](https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html)

<a id="topic-2.1.2.14-11"></a>

###### Aprocitentan (TRYVIO, Idorsia): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “TRYVIO is an endothelin receptor antagonist indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.” |
| Boxed warning | “WARNING: EMBRYO–FETAL TOXICITY” |
| Boxed warning | “Based on animal data TRYVIO may cause fetal harm if used by pregnant patients and is contraindicated in pregnancy.” |
| Recommended dosage | “The recommended dosage of TRYVIO is 12.5 mg orally once daily.” |
| Strengths | “Tablets: 12.5 mg” |
| Warnings and precautions | “ERAs cause hepatotoxicity and liver failure.” |
| Warnings and precautions | “Fluid retention may require intervention” |
| Most common adverse reactions | “Most common adverse reactions (more frequent than placebo and ≥ 2% in TRYVIO-treated patients) are edema/fluid retention and anemia.” |
| Fluid retention | “Edema/fluid retention was reported in 9% of TRYVIO-treated patients compared with 18% of patients receiving aprocitentan 25 mg (twice the recommended dose) and 2% on placebo in the clinical trial, requiring additional diuretic use in some patients.” |
| Hemoglobin | “A decrease in hemoglobin of >2 g/dL from baseline was observed in 7% of patients compared to 1% of placebo patients.” |
| Cardiovascular outcomes | “There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.” |

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Aprocitentan: PRECISION primary endpoint in the prescribing information, sitting systolic blood pressure at week 4

| Sitting systolic blood pressure (mmHg) | TRYVIO 12.5 mg | Placebo |
| --- | --- | --- |
| Participants | “243” | “244” |
| Baseline | “153.2” | “153.3” |
| LS mean change (97.5% CL) | “−15.4 (−17.5, −13.3)” | “−11.6 (−13.7, −9.5)” |
| Difference to placebo, LS mean (97.5% CL) | “−3.8 (−6.8, −0.8)” | “–” |
| p-value | “0.0043” | “–” |

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

> “The primary efficacy endpoint was the change in sitting SBP (SiSBP) from baseline to Week 4 during part 1, measured at trough by unattended automated office blood pressure (uAOBP).”
> “TRYVIO is not approved for use at a 25 mg dose.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Aprocitentan: REMS removed, April 2025

> “This Prior Approval sNDA provides for changes to the approved Tryvio label to remove text regarding the Tryvio REMS and proposed modifications to the approved Tryvio risk evaluation and mitigation strategy (REMS).”
> “a REMS is no longer required for Tryvio.”
> “04/02/2025”

Source: [FDA NDA 217686 supplement approval letter (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217686Orig1s004ltr.pdf)

<a id="topic-2.1.2.14-14"></a>

###### Aprocitentan: commercial availability and approvals outside the United States

> “Aprocitentan is approved as TRYVIO® in the US for the treatment of systemic hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs, and has been commercially available since October 2024.”
> “Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, Switzerland, and Canada.”

Source: [Idorsia press release, aprocitentan commercialization partnership (2026)](https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3793976)

<a id="topic-2.1.2.14-15"></a>

###### Spironolactone (ALDACTONE): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “ALDACTONE is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents.” |
| Dosage in essential hypertension | “The recommended initial daily dose is 25 to 100 mg of ALDACTONE administered in either single or divided doses is recommended.” |
| Titration | “Dosage can be titrated at two-week intervals.” |
| Strengths | “Tablets: 25 mg, 50 mg, and 100 mg” |
| Warnings and precautions | “ALDACTONE can cause hyperkalemia.” |
| Gynecomastia | “ALDACTONE can cause gynecomastia. In RALES, patients with heart failure treated with a mean dose of 26 mg of spironolactone once daily, about 9% of the male subjects developed gynecomastia.” |

Source: [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

###### Spironolactone: PATHWAY-2 trial in drug-resistant hypertension

> “The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001)”
> “In six of the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

<a id="topic-2.1.2.14-17"></a>

###### Eplerenone (INSPRA): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure.” |
| Dosage in hypertension | “The recommended starting dose of INSPRA is 50 mg administered once daily.” |
| Dose increase | “For patients with an inadequate blood pressure response to 50 mg once daily increase the dosage of INSPRA to 50 mg twice daily.” |
| Contraindications for hypertension | “type 2 diabetes with microalbuminuria,” |
| Contraindications for hypertension | “creatinine clearance <50 mL/min, or” |
| Mechanism | “Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone” |

Source: [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

###### Amiloride: randomized comparison with spironolactone in resistant hypertension

> “In this open-label, blinded end-point, randomized clinical trial involving 118 patients with resistant hypertension, amiloride and spironolactone lowered home-measured systolic blood pressure by 13.6 mm Hg and 14.7 mm Hg from baseline, respectively, with no difference in blood pressure–lowering effect.”
> “One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

> “While rates associated with amiloride treatment were unavailable, amiloride has an FDA boxed warning for hyperkalemia, either alone or in combination with hydrochlorothiazide.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-19"></a>

###### Vicadrostat (BI 690517, Boehringer Ingelheim): investigational aldosterone synthase inhibitor studied with empagliflozin

> “Following a recommendation from the independent Data Monitoring Committee (DMC), Boehringer Ingelheim has decided to discontinue the EASi-KIDNEY trial (NCT06531824), one of four studies in the EASi program.”
> “Vicadrostat is an investigational compound and has not received marketing authorization in any country.”
> “EASi program contains three ongoing phase III studies: EASi-HF Preserved, EASi-HF-Reduced and EASi-PROTKT”

Source: [Boehringer Ingelheim press release, EASi-KIDNEY update (2026)](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial)

> “BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals.”

Source: [Tuttle et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38109916/)

<a id="topic-2.1.2.14-20"></a>

###### Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen

> “The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was −12.1 mm Hg (95% CI, −16.5 to −7.6; P < .001) for indapamide, −9.7 mm Hg (95% CI, −12.9 to −6.6; P < .001) for amlodipine, and −4.5 mm Hg (95% CI, −8.2 to −0.8; P = .02) for olmesartan.”
> “Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention.”

Source: [Desai et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12120674/)

> “LSM differences vs placebo in change from baseline to month 3 were −14.1 mm Hg (95% CI, −19.2 to −9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; −16.7 mm Hg (95% CI, −21.2 to −12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and −15.7 mm Hg (95% CI, −20.8 to −10.6; P < .001) with zilebesiran, 600 mg, once every 6 months.”

Source: [Bakris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10873804/)

> “In this global multi-center Phase 3 ZENITH CVOT (NCT07181109), Alnylam and its partner Roche will enroll approximately 11,000 patients in 35 countries to evaluate zilebesiran (300 mg) administered every six months compared to placebo in patients with uncontrolled hypertension with either established CV disease or at high risk for CV disease despite the use of at least two or more antihypertensives.”

Source: [Alnylam press release, ZENITH first patient dosed (2025)](https://www.businesswire.com/news/home/20251001569564/en)

<a id="topic-2.1.2.14-21"></a>

###### Renal denervation: FDA premarket approvals, November 2023

> “The Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “11/07/2023”

Source: [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023)

> “The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “11/17/2023”

Source: [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026)

<a id="topic-2.1.2.14-22"></a>

###### Renal denervation: Medicare coverage with evidence development

> “The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.”
> “On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.1.2.14-23"></a>

###### Renal denervation: sham-controlled trials

> “At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.”

Source: [Kandzari et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244969/)

> “The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle.”

Source: [Azizi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975904/)

> “RDN is an additional option to consider in managing resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.1.2.14-24"></a>

###### Drug-level network meta-analysis in resistant hypertension: office systolic blood pressure

> “Ten RCTs including 2865 participants were analyzed.”
> “The MDs versus placebo were −14.08 mmHg for amiloride (95% CI, −17.40 to −10.77), −10.78 mmHg for spironolactone (95% CI, −13.14 to −8.42), −9.09 mmHg for baxdrostat (95% CI, −11.29 to −6.88), −8.14 mmHg for eplerenone (95% CI, −14.56 to −1.72), and −6.80 mmHg for lorundrostat (95% CI, −8.47 to −5.13).”
> “The MDs were −10.88 mmHg for MRAs (95% CI, −13.29 to −8.48) and −7.56 mmHg for ASIs (95% CI, −9.24 to −5.89).”
> “Although newer ASIs may provide meaningful short‐term BP reductions, equivalence with MRAs cannot be inferred from the current evidence.”
> “Finally, safety outcomes were not quantitatively compared because adverse event reporting was incomplete and inconsistent across trials.”

Source: [Tsou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13587145/)

<a id="topic-2.1.2.14-25"></a>

###### Indirect comparison of lorundrostat and baxdrostat by the Bucher method

> “Five placebo-controlled RCTs (N = 2599) were included.”
> “The lower-dose pair was statistically equivalent (lorundrostat 50 mg vs. baxdrostat 1 mg: mean difference (MD), +0.63 mmHg; P = 0.645); baxdrostat 2 mg produced a modest but significant advantage over lorundrostat 100 mg (MD, +3.56 mmHg; P = 0.043).”
> “Both agents markedly increased hyperkalemia risk (lorundrostat pooled risk ratio (RR), 8.16; baxdrostat pooled RR, 15.12); the between-drug comparison was not significant.”

Source: [Yousif et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13754360/)

<a id="topic-2.1.2.14-26"></a>

###### Bayesian meta-analysis of second-generation aldosterone synthase inhibitors

> “Eight RCTs were included (n = 3,369; 2,430 [72%] randomized to ASI).”
> “However, ASIs increased the odds of hyperkalemia (OR: 7.1; CrI: 3.56, 15.2; τ2 0.23), hyponatremia (OR: 2.6; CrI: 1.25, 5.98; τ2 0.1), and hypotension (OR: 3.28; CrI: 1.43, 8.16; τ2 0.1).”
> “In subgroup analysis, the probability of achieving a clinically meaningful reduction in SBP (MD < −5 mm Hg) was 87.5% with baxdrostat and 94.3% with lorundrostat.”

Source: [Queiroga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13100762/)

<a id="topic-2.1.2.14-27"></a>

###### ICER network meta-analysis, Population 1 (resistant hypertension not at goal): systolic blood pressure versus placebo

| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
| --- | --- |
| Baxdrostat | “-11 (-14.6, -7.3)” |
| Spironolactone | “-10.1 (-13.1, -6.8)” |
| Lorundrostat | “-9 (-16.3, -1.7)” |
| Eplerenone | “-8.9 (-15.5, -2.4)” |
| Amiloride | “-6.6 (-11.5, -1.5)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Although treatment with baxdrostat or lorundrostat did not result in statistically significant decreases in SBP over spironolactone, eplerenone, or amiloride, 95% credible intervals were wide and included potentially clinically significant differences in both directions.”
> “Note: Each box represents the estimated treatment difference and 95% credible interval for the combined direct and indirect comparisons between two drugs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-28"></a>

###### ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo

| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
| --- | --- |
| Baxdrostat | “-10.1 (-16.6, -3.9)” |
| Lorundrostat | “-8.6 (-12.4, -4.8)” |
| Amlodipine | “-8.3 (-10.7, -6.2)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, neither baxdrostat nor lorundrostat showed a statistically significant difference in SBP reduction compared with amlodipine, with very small differences between the drugs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-29"></a>

###### ICER comparative evidence ratings

| Population | Treatment | Comparator | Evidence rating |
| --- | --- | --- | --- |
| “Populations 1 and 2” | “Baxdrostat” | “Lorundrostat” | “I” |
| “Populations 1 and 2” | “Baxdrostat or Lorundrostat” | “Spironolactone, Eplerenone, or Amiloride” | “P/I” |
| “Population 3” | “Baxdrostat” | “Lorundrostat” | “I” |
| “Population 3” | “Baxdrostat or Lorundrostat” | “Amlodipine” | “C-” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, ASIs such as baxdrostat and lorundrostat may be better tolerated than spironolactone and may result in greater blood pressure reductions than comparator drugs, though trials are only short-term.”
> “Finally, there are not yet data on the direct impact of baxdrostat and lorundrostat on patient-important outcomes such as cardiovascular events, kidney disease, dementia, quality of life, or mortality; the other comparators in our review have demonstrated a positive impact on patient-important outcomes.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-30"></a>

###### Hyperkalemia at 12 weeks across aldosterone-pathway drugs

| Drug | Arm | n | Hyperkalemia, % |
| --- | --- | --- | --- |
| Baxdrostat | “BAX 1 mg” | “333” | “6.6” |
| Baxdrostat | “BAX 2 mg” | “441” | “10.2” |
| Baxdrostat | “Placebo” | “442” | “2.5” |
| Lorundrostat | “LOR 50 mg” | “635” | “2.5” |
| Lorundrostat | “Placebo” | “367” | “0.3” |
| Spironolactone | “SPIR 15-50 mg” | “2748” | “17.5” |
| Spironolactone | “Placebo” | “2760” | “7.5” |
| Eplerenone | “EPL 25-50 mg” | “5282” | “5” |
| Eplerenone | “Placebo” | “5275” | “2.6” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, use of MRA medications is often limited by side effects, most prominently hyperkalemia and gynecomastia.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-31"></a>

###### Drug costs used by ICER for the comparators

| Drug | Net price per year |
| --- | --- |
| “Spironolactone (25 mg)” | “$43” |
| “Spironolactone (100 mg)” | “$171” |
| “Eplerenone (50 mg)” | “$511” |
| “Eplerenone (100 mg)” | “$1,022” |
| “Amiloride (5 mg)” | “$206” |
| “Amiloride (10 mg)” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets).”
> “For lorundrostat, we used the baxdrostat WAC price as a placeholder price.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Yusuf et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13232938/); [Elbahloul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41645642/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Blood pressure categories: 2025 AHA/ACC guideline

> “Blood pressure is classified by the following framework: normal blood pressure is defined as <120 mm Hg systolic and <80 mm Hg diastolic; elevated blood pressure as 120 to 129 mm Hg systolic and <80 mm Hg diastolic; stage 1 hypertension as 130 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic; and stage 2 hypertension as ≥140 mm Hg systolic or ≥90 mm Hg diastolic.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-2"></a>

###### Treatment goal and controlled hypertension

> “The overarching blood pressure treatment goal is <130/80 mm Hg for all adults, with additional considerations for those who require institutional care, have a limited predicted lifespan, or are pregnant.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Controlled hypertension: Among those with hypertension, defined as having systolic blood pressure below 130 mm Hg and diastolic blood pressure below 80 mm Hg.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.1-3"></a>

###### Uncontrolled hypertension: definition in a US real-world prevalence study

> “Hypertension (HTN) is classified as uncontrolled (uHTN) when systolic or diastolic blood pressure (BP) is greater than 130/80 mm Hg despite patients receiving anti-hypertensive treatments (AHTs).”
> “HTN is classified as resistant (rHTN) when it remains uncontrolled despite patients receiving at least 3 AHTs, or when it is controlled and patients receive at least 4 AHTs.”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-2.2.1.1-4"></a>

###### Resistant hypertension definition: 2025 AHA/ACC guideline

> “Resistant hypertension is defined as BP above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses or BP at goal but requiring ≥4 medications (Figure 8).”
> “Evaluation of resistant hypertension requires exclusion of pseudoresistance, including inaccurate BP measurement”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-5"></a>

###### Controlled, uncontrolled, and apparent treatment-resistant hypertension: AHA scientific statement

> “RH is defined as the BP of a hypertensive patient that remains elevated above goal despite the concurrent use of 3 antihypertensive agents of different classes, commonly including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]), and a diuretic.”
> “RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications, a condition that has been referred to in the literature as controlled RH. Thus, the term RH refers to hypertension with both uncontrolled and controlled BP, depending on the number of antihypertensive agents used.”
> “The term apparent treatment RH (aTRH) is used when ≥1 of the following data elements are missing: medication dose, adherence, or out-of-office BP; thus, pseudoresistance cannot be excluded.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.1-6"></a>

###### Resistant hypertension definition: European guidelines

> “Hypertension is defined as resistant when a treatment strategy including appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a calcium channel blocker fail to lower office systolic and diastolic BP values to <140 mmHg and/or <90 mmHg, respectively.”
> “Resistant hypertension is not a disease, but an indicator that should be used to identify patients at high risk for CVD, in which secondary hypertension is also frequent;”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

> “In the 2018 Guidelines, hypertension was defined as resistant to treatment when appropriate lifestyle measures and treatment with optimal or best tolerated doses of three or more drugs (a Thiazide/Thiazide-like diuretic, an RAS blocker and a CCB) fail to lower office BP to <140/90 mmHg”
> “Evidence of adherence to therapy and exclusion of secondary causes of hypertension are required to define true resistant hypertension, otherwise resistant hypertension is only apparent and termed as pseudoresistant hypertension (Fig. 13).”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.1.1-7"></a>

###### Etiology of primary hypertension: behavioral, environmental, hormonal, and genetic factors

> “Elevated BP and hypertension reflect a complex interplay of behavioral, environmental, hormonal, and genetic influences across the lifespan (Table 8).”
> “Among dietary factors influencing BP, higher sodium intake, lower potassium intake (measured by urinary excretion), and alcohol overuse predominate; low intake of fiber, calcium, magnesium, and plant protein also influence BP.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The causes of hypertension are multifactorial, including genetics, environmental (e.g., air pollution), dietary influences (e.g., high sodium intake, alcohol), medical conditions (e.g., primary aldosteronism, obesity, sleep disordered breathing, or kidney, thyroid, or adrenal disease), and psychosocial stressors.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.1-8"></a>

###### Risk factors and demographic correlates of resistant hypertension

> “Multiple cohort studies have identified common risk factors for resistant hypertension, including older age, obesity, CKD, and diabetes.”
> “Resistant hypertension is more common in Black populations, which may be related to adverse social factors, including living in a professional shortage area or disadvantaged neighborhood and clinical inertia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Demographic correlates of RH include black race, older age, and male sex.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.1-9"></a>

###### Secondary hypertension: settings and common causes

> “Secondary hypertension is more common with stage 2 hypertension, treatment-resistant hypertension, sudden onset of hypertension, increased BP in patients with hypertension previously controlled on drug therapy, early-onset hypertension (age <30 years), diastolic hypertension in older adults, and target organ damage disproportionate to the duration or severity of the hypertension.”
> “Common forms of secondary hypertension include primary aldosteronism and obstructive sleep apnea (OSA).”
> “Secondary hypertension is more common among adults with resistant hypertension, particularly primary aldosteronism, OSA, renal parenchymal disease, and renovascular disease.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-10"></a>

###### Interfering medications

> “Approximately 20% of adults with hypertension reported regular use of over-the-counter or nonprescription medications that may directly raise BP or interfere with antihypertensive drug efficacy, such as NSAIDs or nasal decongestants (Table 17).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-11"></a>

###### Primary aldosteronism: definition and adrenal subtypes

> “Primary aldosteronism is defined as a group of disorders in which aldosterone production is inappropriately high for sodium and volume status, is relatively autonomous of the major regulators of aldosterone secretion (angiotensin II and potassium), and cannot be completely suppressed with sodium loading.”
> “In two-thirds of patients with primary aldosteronism, excess aldosterone is caused by bilateral adrenal hyperplasia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-12"></a>

###### Primary aldosteronism prevalence by hypertension severity: 2025 AHA/ACC guideline

> “Primary aldosteronism is a common cause of secondary hypertension (occurring in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension), and targeted treatment is associated with improved kidney and cardiovascular outcomes.”
> “The prevalence of primary aldosteronism is approximately 5% to 10% among individuals with stage 1 hypertension and 11% to 22% among individuals with stage 2 hypertension, which varies depending on the modality of testing and testing thresholds used to diagnose primary aldosteronism.”
> “The prevalence of primary aldosteronism may be similar among individuals with stage 2 hypertension and those with resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-13"></a>

###### Primary aldosteronism in resistant hypertension: cohort studies with confirmatory testing

> “Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension; corresponding adjusted prevalence estimates for biochemically overt primary aldosteronism were 11.3% (CI, 5.9% to 16.8%), 15.7% (CI, 8.6% to 22.9%), 21.6% (CI, 16.1% to 27.0%), and 22.0% (CI, 17.2% to 26.8%).”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

> “Over 20 years, we studied 1616 patients with resistant hypertension.”
> “On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis. Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).”

Source: [Douma et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18539224/)

> “In this prospective study of 88 consecutive patients referred to a university clinic for resistant hypertension, we determined the 24-hour urinary aldosterone excretion during high dietary salt ingestion, baseline plasma renin activity, and plasma aldosterone in all subjects.”
> “Eighteen subjects (20%) were confirmed to have primary hyperaldosteronism. The prevalence of hyperaldosteronism was similar in black and white subjects.”

Source: [Calhoun et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12468575/)

<a id="topic-2.2.1.1-14"></a>

###### Primary aldosteronism in resistant hypertension: review estimates

> “Primary aldosteronism (PA) is the leading cause of secondary hypertension, affecting at least 10% of all hypertensive patients and up to 25% of those with treatment-resistant hypertension, and is associated with markedly increased cardiovascular, metabolic, and kidney morbidity due to the systemic effects of excess aldosterone.”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

> “Primary aldosteronism, which is characterized by excessive production of aldosterone, is one of the most common causes of treatment-resistant hypertension; between 11-30% of people with treatment-resistant hypertension are estimated to have primary aldosteronism.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.1-15"></a>

###### Aldosterone dysregulation in uncontrolled and resistant hypertension: company statement

> “Dysregulated aldosterone levels are a key factor in uHTN or rHTN in approximately 30% of patients.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.2.1.1-16"></a>

###### Obstructive sleep apnea and renovascular disease in resistant hypertension

> “Very high proportions (60%−84%) of individuals with RH have sleep apnea.”
> “Hypertension accelerated or worsened by renal artery stenosis remains among the most common causes of RH, particularly in older age groups.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Atherosclerotic renovascular disease may be present in 14% to 40% of adults with hypertension; however, only a small fraction (0.1% to 5%) is considered to be hemodynamically significant to result in renovascular hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Hypertension

<a id="topic-2.2.1.2.1-1"></a>

###### Lifetime risk of hypertension: US pooled cohorts

> “Data from 13 160 participants in cohorts in the Cardiovascular Lifetime Risk Pooling Project (ie, the Framingham Offspring Study, CARDIA, and ARIC) showed that the lifetime risk of hypertension from 20 to 85 years of age according to the 2017 Hypertension Clinical Practice Guidelines was 86.1% (95% CI, 84.1%–88.1%) for Black males, 85.7% (95% CI, 84.0%–87.5%) for Black females, 83.8% (95% CI, 82.5%–85.0%) for White males, and 69.3% (95% CI, 67.8%–70.7%) for White females.”

Source: [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)

> “Among middle-aged individuals, the remaining lifetime risks for incident hypertension are as high as 80% to 90%, with earlier onset among men compared with women, and for Black and Hispanic compared with White and Chinese Americans.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.2.1-2"></a>

###### Cumulative incidence of hypertension by age 55 years: CARDIA

> “Among 3890 participants without hypertension at baseline (aged 18–30 years), cumulative incidence of hypertension by age 55 years was 75.5%, 75.7%, 54.5%, and 40.0% in black men, black women, white men, and white women, respectively.”

Source: [Thomas et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6064834/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence of resistant hypertension after starting treatment: two US integrated health plans

> “Among 205,750 patients with incident hypertension, 1.9% developed resistant hypertension within a median 1.5 years from initial treatment, or 0.7 cases per 100 person-years of follow-up.”
> “Among patients with incident hypertension started on treatment, 1 in 50 patients developed resistant hypertension.”
> “In addition, we have shown that approximately 1 in 6 patients on 3 or more hypertension medications will continue to meet criteria for resistant hypertension over follow-up.”

Source: [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)

<a id="topic-2.2.1.2.1-4"></a>

###### Incidence of apparent treatment-resistant hypertension: Thai hospital cohort, 2010 to 2024

> “Among 114,364 hypertensive patients, the incidence of aRHT was 2.61 per 100 person-years (95% confidence interval [CI], 2.56–2.65).”
> “Among HT patients who were initially complication-free, the probabilities of developing aRHT were 9.63% (95% CI, 9.39–9.88) at 5 years and 15.19% (95% CI, 14.80–15.59) at 10 years.”

Source: [Teza et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875774/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Hypertension

<a id="topic-2.2.1.2.2-1"></a>

###### Hypertension prevalence: NHANES August 2021 to August 2023

> “During August 2021–August 2023, the prevalence of adult hypertension was 47.7%. Hypertension was higher in men (50.8%) than women (44.6%) and increased with age: 23.4% for ages 18–39, 52.5% for 40–59, and 71.6% for 60 and older.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.2.2-2"></a>

###### Awareness, treatment, and control: NHANES August 2021 to August 2023

> “Among adults with hypertension, 59.2% were aware of their hypertension”
> “More than one-half of adults with hypertension were currently taking medication (51.2%) to lower blood pressure.”
> “About one-fifth of adults with hypertension had their blood pressure controlled (20.7%) to less than 130/80 mm Hg.”
> “No significant change was seen between 2017–March 2020 and August 2021–August 2023 in the prevalence of hypertension awareness (60.2% compared with 59.2%), treatment (50.3% and 51.2%), or control (22.2% and 20.7%) among adults with hypertension (Figure 5, Table 5).”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### Hypertension prevalence, uncontrolled blood pressure, and race: CDC

> “Nearly half of adults have high blood pressure (48.1%, 119.9 million).”
> “About half of adults (45%) with uncontrolled high blood pressure have a blood pressure of 140/90 mmHg or higher.”
> “About 34 million adults who may need blood pressure medicine according to the hypertension guidelines are not currently taking it.”
> “High blood pressure is more common in non-Hispanic black adults (59.6%) than in Hispanic adults (44.9%), non-Hispanic white adults (44.8%), or non-Hispanic Asian adults (42.7%)”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

> “From 2017 to 2020, the prevalence of hypertension (defined as BP ≥130/80 mm Hg or receiving antihypertensive therapy) among adults in the United States was 46.7%, with the prevalence varying by age, sex, and race/ethnicity (Table 5).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.2.2-4"></a>

###### Treated but uncontrolled hypertension: Million Hearts cascade, NHANES 2017 to 2020

> “Nearly half of adults have hypertension (119.9 million).”
> “Many adults who are already treated with antihypertensive medication(s) may need to have their current medication dosage increased or to be prescribed additional medications to achieve blood pressure control (33.2 million). More than half of this group have blood pressure ≥140/90 mm Hg (18.8 million).”
> “Many adults for whom hypertension medication is recommended by a clinician are untreated (34.8 million).”

Source: [Million Hearts hypertension cascade (2023)](https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html)

<a id="topic-2.2.1.2.2-5"></a>

###### Blood pressure control trends: NHANES 1999 to 2018

> “In this serial cross-sectional study that included 18 262 US adults aged 18 years or older with hypertension, with data weighted to be representative of the US population, the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.”
> “Among adults taking antihypertensive medication, the age-adjusted estimated proportion with controlled BP increased from 53.4% (95% CI, 49.0%-57.9%) in 1999-2000 to 68.3% (95% CI, 65.9%-70.8%) in 2007-2008, remained stable and was 72.2% (95% CI, 68.6%-75.8%) in 2013-2014, and then declined to 64.8% (95% CI, 61.3%-68.3%) in 2017-2018 (part B in the Figure).”

Source: [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/)

<a id="topic-2.2.1.2.2-6"></a>

###### Uncontrolled hypertension above goal: ICER

> “Despite effective treatments, more than 70% of adults with hypertension have not reached their goal blood pressure (i.e., blood pressure remains ≥130/80 mm Hg for most people),”
> “Almost seven million Americans are estimated to have apparent treatment-resistant hypertension, which is defined as a blood pressure above goal while a person is on three or more antihypertensive medications (ACEi/ARB + CCB + thiazide diuretic) at maximally tolerated doses or a blood pressure at goal on four or more antihypertensive medications.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.2.2-7"></a>

###### Apparent treatment-resistant hypertension: NHANES 2003 to 2020

> “Apparent treatment resistant hypertension (aTRH) was defined as patients on a diuretic, either with a systolic blood pressure (BP) ≥130 or diastolic BP ≥80 mmHg while on 3 medications or those on ≥ 4 medications regardless of BP.”
> “Of 24,579 adults with HTN, 1,939 had aTRH (42.4% male, 19.9% Black), corresponding to a weighted total of 6,989,821 US patients. Among hypertensive adults, the prevalence of aTRH was 6.41% (95% CI 5.97-6.88%) and remained stable over time. Over the study duration, aTRH prevalence among adults on treatment decreased from 17.7% to 12.6%. The overall prevalence of hypertension rose from 50.1% to 54.0%, while the prevalence of uncontrolled BP decreased from 75.0% to 68.7%.”
> “aTRH was most strongly associated with older patients, those of Black race, higher BMI, and more advanced cardiovascular comorbidities.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.1.2.2-8"></a>

###### Apparent treatment-resistant hypertension: NHANES 2009 to 2014, 2008 and 2018 AHA definitions

> “The prevalence of aTRH was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively (Δ=2.0%; 95%CI 1.5%, 2.7%). Overall, 10.3 million US adults had aTRH according to the 2018 Scientific Statement.”

Source: [Carey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/)

<a id="topic-2.2.1.2.2-9"></a>

###### Resistant hypertension prevalence: guideline and scientific statement estimates

> “Based on the current BP goal of <130/80 mm Hg, the prevalence of resistant hypertension is approximately 8.5% to 20% among hypertensive US adults.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based”
> “and 15% to 18% of clinic-based reports.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “It has a lower prevalence after removal of patients with normal out-of-office BP values, and the percentage of patients removed for this reason has been found to vary from about 14% to about 37% in meta-analyses of observational studies, randomized trials, surveys and registries”
> “After applying the strict criteria outlined above, a reasonable estimate of the resistant hypertension prevalence is that it might involve about 5% of the overall hypertensive population.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.1.2.2-10"></a>

###### Controlled and uncontrolled resistant hypertension: Kaiser Permanente Southern California

> “Resistant hypertension was identified in 60,327 (12.8%) individuals of whom 23,104 met our criteria for cRH and 37,223 met our criteria for uRH. Thus, uRH accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.2.2-11"></a>

###### Uncontrolled and resistant hypertension: US real-world patient funnel, Optum Market Clarity, 2018 to 2025

> “Based on Optum Market Clarity Data used in this study, 53.8% of treated patients have uHTN, corresponding to 104 494 patients in the standardized funnel.”
> “Based on the number of patients with 3+ AHTs, rHTN prevalence among adults with HTN is estimated at 9.8%.”
> “This patient funnel provides estimates of uHTN and rHTN prevalence among adult patients with HTN based on large-scale real-world data (i.e., 27.6% and 9.8%, respectively).”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-2.2.1.2.2-12"></a>

###### Company statement of US prevalence

> “In the United States, there are approximately 120 million patients with sustained elevated BP, or hypertension. Approximately 60 million patients are treated and over 30 million do not achieve their BP goal, with approximately 20 million having systolic BP levels greater than 140 mmHg.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.2.1.2.2-13"></a>

###### Global resistant hypertension prevalence: meta-analysis of 91 studies

> “In the general, population of treated patients with hypertension, the prevalence of true-resistant, apparent treatment-resistant and pseudo-resistant hypertension were 10.3% (95% CI 7.6% to 13.2%), 14.7% (95% CI 13.1% to 16.3%) and 10.3% (95% CI 6.0% to 15.5%).”

Source: [Noubiap et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30087099/)

<a id="topic-2.2.1.2.2-14"></a>

###### Global hypertension prevalence, treatment, and control

> “An estimated 1.4 billion adults aged 30–79 years worldwide had hypertension in 2024; this represents 33% of the popluation in this age range.”
> “Approximately 630 million adults with hypertension (44%) are diagnosed and treated.”
> “Approximately 320 million adults with hypertension (23%) have it under control.”

Source: [World Health Organization hypertension fact sheet (2025)](https://www.who.int/news-room/fact-sheets/detail/hypertension)

> “The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence.”
> “Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men.”

Source: [NCD Risk Factor Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446938/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Age-related rise in blood pressure

> “With aging, population SBP levels tend to rise steadily to the end of life, whereas DBP levels rise until the fifth decade of life, plateau for a decade, and decline thereafter.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-2"></a>

###### Blood pressure and vascular mortality: one million adults in 61 prospective studies

> “At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.”
> “Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.”

Source: [Lewington et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12493255/)

> “Meta-analyses of observational studies have demonstrated that elevated BP and hypertension are associated with a higher risk of CVD, end-stage kidney disease, subclinical atherosclerosis, and all-cause death.”
> “Hypertension is the most prevalent modifiable CVD risk factor and is the leading cause of death and disability worldwide, with an increasing burden over the last several decades.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-3"></a>

###### US mortality attributed to high blood pressure

> “In 2024, high blood pressure was a primary or contributing cause of 680,179 deaths in the United States”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

> “The 2022 age-adjusted death rate attributable primarily to HBP was 31.5 per 100 000.”
> “From 2012 to 2022, the age-adjusted death rate attributable to HBP increased 63.2%, and the actual number of deaths attributable to HBP rose 93.0%.”
> “When any mention of HBP was present, the overall age-adjusted death rate in 2022 was 163.1 per 100 000.”

Source: [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)

<a id="topic-2.2.1.3-4"></a>

###### Global mortality

> “Hypertension is a major cause of premature death worldwide.”

Source: [World Health Organization hypertension fact sheet (2025)](https://www.who.int/news-room/fact-sheets/detail/hypertension)

<a id="topic-2.2.1.3-5"></a>

###### Hypertensive emergency: in-hospital and one-year outcomes

> “Patients with hypertensive emergencies experience a high in-hospital mortality rate of 10% with a 1-year cardiovascular morbidity and mortality rate of 20% to 30%.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-6"></a>

###### Resistant hypertension prognosis: guideline statements

> “Patients with resistant hypertension are known to have at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death than adults with hypertension without resistance to treatment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

> “Importantly, it has been demonstrated that patients with resistant hypertension are at a higher risk of end-organ damage and have a nearly 50% greater risk for cardiovascular events and mortality as compared to those with non-resistant disease.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.1.3-7"></a>

###### Resistant hypertension prognosis: incident treated hypertension in two US health plans

> “Over 3.8 years of median follow-up, cardiovascular event rates were significantly higher in those with resistant hypertension (unadjusted: 18.0% vs. 13.5%, p<0.001). After adjusting for patient and clinical characteristics, resistant hypertension was associated with a higher risk of cardiovascular events (HR 1.47, 95% CI 1.33–1.62).”

Source: [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)

<a id="topic-2.2.1.3-8"></a>

###### Resistant hypertension prognosis: renal, cardiovascular, and mortality outcomes in 470,386 individuals

> “Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.”
> “The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.3-9"></a>

###### Resistant hypertension prognosis: ambulatory confirmation and mortality, Spanish ABPM registry

> “Compared with controlled hypertension, resistant hypertension was associated with an increased risk in all-cause (HR, 1.21 [95% CI, 1.12-1.30]) and cardiovascular mortalities (HR, 1.33 [95% CI, 1.17-1.51]) in confounder-adjusted models.”
> “When ABPM-confirmed and white-coat resistant hypertension were separately compared with controlled hypertension, only the former was associated with an increased risk of death and cardiovascular death (HR, 1.36 [95% CI, 1.26-1.48] and 1.56 [95% CI, 1.36-1.79]), respectively.”

Source: [de la Sierra et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39247961/)

<a id="topic-2.2.1.3-10"></a>

###### Resistant hypertension prognosis: Thai hospital cohort

> “Regarding the prognosis of aRHT, compared to non-aRHT patients, those with aRHT had significant higher risk of CAD, CKD, HF, and all-cause mortality with hazard ratios (95% CI) of 1.80 (1.56–2.08), 1.93 (1.79–2.08), 4.24 (3.54–5.08), and 2.84 (1.89–4.27), respectively.”

Source: [Teza et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875774/)

<a id="topic-2.2.1.3-11"></a>

###### Effect of blood pressure control within resistant hypertension

> “Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.”
> “BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.3-12"></a>

###### Mortality with hypertension uncontrolled on two or more medications: company statement

> “Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to either cardiovascular disease or stroke, respectively.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Primary aldosteronism: renin-independent aldosterone production and volume expansion

> “Primary aldosteronism is defined as a group of disorders in which aldosterone production is inappropriately high for sodium and volume status, is relatively autonomous of the major regulators of aldosterone secretion (angiotensin II and potassium), and cannot be completely suppressed with sodium loading.”
> “The increased production of aldosterone induces intravascular volume expansion, suppressed plasma renin activity, sodium retention, increased potassium excretion, hypertension, and cardiovascular and kidney damage.”
> “Primary aldosteronism is a common cause of secondary hypertension (occurring in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension), and targeted treatment is associated with improved kidney and cardiovascular outcomes.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-2"></a>

###### Continuum of renin-independent aldosterone production across blood pressure categories

> “Participants with normotension (n = 289), stage 1 hypertension (n = 115), stage 2 hypertension (n = 203), and resistant hypertension (n = 408).”
> “Every blood pressure category had a continuum of renin-independent aldosterone production, where greater severity of production was associated with higher blood pressure, kaliuresis, and lower serum potassium levels.”
> “Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension”
> “Beyond this categorical definition of primary aldosteronism, there is a prevalent continuum of renin-independent aldosterone production that parallels the severity of hypertension.”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

<a id="topic-2.2.1.4-3"></a>

###### Mineralocorticoid receptor activation and target organ injury

> “This renin-independent aldosterone production can cause hypertension, but interactions with the mineralocorticoid receptor also cause hypokalemia and increased risk for adverse cardiovascular outcomes”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

> “Chronic renin-angiotensin-aldosterone system activation and excess aldosterone exert detrimental effects on the heart and the kidneys via contributing to inflammation, fibrosis, and dysfunction in the myocardium, vasculature, and the kidneys.”
> “These effects are purported to be through genomic mineralocorticoid receptor (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent actions.”
> “Because both hyperkalemia and excess aldosterone are associated with progression of CKD and HF, and MRA therapy is associated with elevations in aldosterone levels, patients on MRA therapy may remain at a high residual risk for poor outcomes even on MRA therapy.”

Source: [Fioretti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40738563/)

> “Patients with primary aldosteronism are at greater risk for target organ damage than those with primary hypertension due to the toxic tissue effects of aldosterone even when adjusted for degree of hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-4"></a>

###### Aldosterone excess and intravascular volume expansion in resistant hypertension

> “Consecutive subjects with resistant hypertension (RHTN) (n=279) and controls (n=53) were prospectively evaluated for plasma aldosterone (PAC), plasma renin activity (PRA), aldosterone-renin ratio (ARR), brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), 24-hr urinary aldosterone (UAldo), cortisol (UCort), sodium (UNa) and potassium (UK) on their routine diet.”
> “PAC (13±0.5 vs. 8.4±0.7 ng/dl, p=0.0005), ARR (22±1.7 vs. 6±0.7, p < 0.0001), UAldo (13±0.6 vs. 9.7±0.9 μg/24hr, p=0.02), BNP (37.2±3.1 vs. 22.5±3.4 pg/ml, p=0.007) and ANP (95.9±5.8 vs. 54.8±4.9 pg/ml, p=0.001) were higher, PRA (2.3±0.2 vs. 3.8±0.9 ng/ml/hr, p=0.02) and serum potassium (3.9±0.03 vs. 4.3±0.06 mEq/L, p < 0.0001) were lower in patients with RHTN compared to controls.”
> “These findings indicate that aldosterone levels are higher and there is evidence of intravascular volume expansion (higher BNP and ANP levels) in patients with resistant hypertension compared to controls.”

Source: [Gaddam et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748247/)

<a id="topic-2.2.1.4-5"></a>

###### Renin suppression and sodium retention in resistant hypertension

> “and suppressed circulating renin levels (≈60% of those with RH have suppressed renin levels).”
> “In general, RH is characterized by exquisite salt sensitivity of BP.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).”
> “Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately high aldosterone concentrations.”
> “Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; p<0·0001) with spironolactone, but not other treatments.”
> “Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to inappropriate aldosterone secretion.”
> “Mineralocorticoid receptor blockade by spironolactone overcomes the salt retention and resistance of hypertension to treatment.”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.1.4-6"></a>

###### Obesity: visceral adiposity and mineralocorticoid activity

> “Visceral adiposity in particular plays a fundamental role in causing high BP through a variety of mechanisms culminating in enhanced salt sensitivity, vascular dysfunction, and activation of the sympathetic nervous system and renin-angiotensin system.”
> “Mounting evidence further supports the importance of heightened mineralocorticoid activity in RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Multiple cohort studies have identified common risk factors for resistant hypertension, including older age, obesity, CKD, and diabetes.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-7"></a>

###### Chronic kidney disease: impaired sodium excretion and volume expansion

> “CKD is both a cause and a complication of poorly controlled hypertension.”
> “Reduced kidney function results in impaired salt excretion, overactivation of the renin-angiotensin-aldosterone system, increased sympathetic nervous system activity, and altered medication efficacy.”
> “Treatment resistance in patients with CKD is undoubtedly related in large part to increased sodium and fluid retention and consequential intravascular volume expansion.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.4-8"></a>

###### Obstructive sleep apnea: fluid retention and aldosterone excess

> “OSA is extremely common in patients with RH, with prevalence rates as high as 70% to 90%, and when present, OSA is often severe.”
> “The high occurrence of OSA in patients with RH has been attributed to increased fluid retention and accompanying upper airway edema, as suggested by studies positively relating the presence and severity of OSA to aldosterone excess and high dietary sodium intake.”
> “The role of aldosterone in promoting OSA is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of OSA in patients with RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Additionally, patients with resistant hypertension (regardless of whether hypokalemia is present), hypertension with hypokalemia (either spontaneous or diuretic-induced), and hypertension with OSA have a relatively high prevalence of primary aldosteronism (∼20%-35%).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Office blood pressure measurement: standardized protocol

> “Accurate measurement of BP is essential to diagnose high BP, ascertain BP-related CVD risk, and assess response to therapy.”
> “Office BP should be based on the average of available readings, and an average of ≥2 BP measurements obtained on ≥2 separate occasions may minimize error and provide a more accurate estimation of office BP.”
> “Mean unattended AOBP is lower than mean office BP obtained with a clinician present and using a standardized protocol.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-2"></a>

###### Out-of-office blood pressure: home and ambulatory monitoring

> “Out-of-office BP monitoring with either ABPM or HBPM provides valuable and distinct information compared with office BP for confirming the diagnosis of hypertension.”
> “ABPM is preferred for excluding white-coat hypertension and masked hypertension among individuals not taking antihypertensive medication.”
> “However, HBPM is preferred for excluding a white-coat effect and masked uncontrolled hypertension among individuals taking antihypertensive medication as ABPM is more difficult to conduct repeatedly in clinical practice.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.”

Source: [US Preventive Services Task Force (2021)](https://jamanetwork.com/journals/jama/fullarticle/2779190)

<a id="topic-2.2.1.5-3"></a>

###### Out-of-office thresholds corresponding to office blood pressure

| Office, mm Hg | HBPM, mm Hg | Daytime ABPM, mm Hg | Nighttime ABPM, mm Hg | 24-Hour ABPM, mm Hg |
| --- | --- | --- | --- | --- |
| “130/80” | “130/80” | “130/80” | “110/65” | “125/75” |
| “140/90” | “135/85” | “135/85” | “120/70” | “130/80” |

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-4"></a>

###### Pseudoresistance: confirmation of true treatment resistance

> “Evaluation of resistant hypertension requires exclusion of pseudoresistance, including inaccurate BP measurement”
> “Routine measurement of out-of-office BP is an important component of resistant hypertension management as both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Assessment for treatment adherence and use of ABPM (or home BP monitoring if ABPM is unavailable) are needed to confirm RH.”
> “Inaccurate measurement of BP can result in the appearance of treatment resistance.”
> “In this study of patients referred for RH, inaccurate BP measurement was estimated at 33%.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “In addition, excluding pseudo-resistance is a prerequisite.”
> “Specifically, pseudo-resistance indicates poor adherence to BP-lowering treatment, which should be verified by careful questioning of the patient in the first instance (Section 7.4.3).”
> “In addition, white-coat hypertension must be excluded.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.5-5"></a>

###### White-coat effect in apparent treatment-resistant hypertension

> “A clinically significant white-coat effect may be present in 28% to 39% of individuals with aTRH by office BP measurement.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Among them, 8295 (12.2% of the database) had resistant hypertension (office blood pressure ≥140 and/or 90 mm Hg while being treated with ≥3 antihypertensive drugs, 1 of them being a diuretic).”
> “After ambulatory blood pressure monitoring, 62.5% of patients were classified as true resistant hypertensives, the remaining 37.5% having white-coat resistance.”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

> “Therefore, it is reasonable to exclude a white-coat effect using out-of-office BP monitoring for individuals with apparent resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-6"></a>

###### Medication nonadherence: prevalence and adherence testing

> “Studies have documented that up to 50% of patients do not adhere to their antihypertensive medications after 1 year of treatment.”
> “Adherence to medications can be assessed in multiple ways, including self-report, medication adherence questionnaires, review of prescription refills, pill counting, electronic pill boxes, and chemical adherence testing of antihypertensive drug levels (Table 15).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “the pooled prevalence of nonadherence was 31.2%”
> “with nonadherence rates ranging from 3.3 to 86.1%.”
> “The strongest contributor to variance in nonadherence rates was the method of adherence assessment used.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

> “There is no gold standard for measuring adherence.”
> “A direct method such as urine or blood measurement of drug or metabolites is considered more robust but is relatively expensive, is of limited availability, and does not perfectly reflect level of adherence.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should also be considered, if resources allow.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.5-7"></a>

###### Primary aldosteronism screening: 2025 Endocrine Society guideline

> “We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.”

Source: [Adler et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40658480/)

> “the 2025 Endocrine Society guideline extends screening recommendations beyond high-risk subgroups to encompass all adults with hypertension, issuing a conditional (Grade 2) recommendation.”
> “Specifically, a positive screen is defined by a suppressed renin – plasma renin activity (PRA) ≤1 ng/mL/h or direct renin concentration (DRC) ≤8.2 mU/L – in combination with inappropriately elevated aldosterone (≥10 ng/dL by immunoassay or ≥7.5 ng/dL by liquid chromatography), and an elevated ARR (aldosterone [ng/dL] to PRA [ng/mL/h] ratio >20 or aldosterone [pmol/L] to DRC [mU/L] ratio >70).”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

<a id="topic-2.2.1.5-8"></a>

###### Primary aldosteronism screening: 2025 AHA/ACC guideline

> “In adults with resistant hypertension, screening for primary aldosteronism is recommended regardless of whether hypokalemia is present to increase rates of detection, diagnosis, and specific targeted therapy.”
> “Patients with primary aldosteronism typically have suppressed renin activity (<1 ng/mL/h).”
> “The most commonly used cutoff value for the aldosterone to renin activity ratio is 30 when plasma aldosterone concentration is reported in nanograms per deciliter (ng/dL) and plasma renin activity in nanograms per milliliter per hour (ng/mL/h), although some data support alternative thresholds (20 or 40).”
> “Initial screening for primary aldosteronism can typically be interpreted in the context of most medications that affect renin and aldosterone.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-9"></a>

###### Primary aldosteronism screening: sensitivity of the aldosterone-to-renin ratio

> “The aldosterone–renin ratio had poor sensitivity and negative predictive value for detecting biochemically overt primary aldosteronism.”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

<a id="topic-2.2.1.5-10"></a>

###### Primary aldosteronism screening rates in practice

> “However, the rate of screening for primary aldosteronism in guideline-recommended individuals is <2% in the United States.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “After a median follow-up of 3.3 years (IQR, 1.0 to 6.7 years) after meeting criteria for apparent treatment-resistant hypertension, 4277 (1.6%) patients had testing for primary aldosteronism.”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Asymptomatic presentation: elevated blood pressure without signs or symptoms

> “Most people with high blood pressure, also called hypertension, have no signs or symptoms.”
> “High blood pressure usually has no signs or symptoms, so many people do not know they have it.”
> “The only way to know if you have high blood pressure is to measure your blood pressure regularly.”

Source: [CDC About High Blood Pressure (2026)](https://www.cdc.gov/high-blood-pressure/about/index.html)

> “about 1 in 6 adults with high blood pressure is unaware of it and would not report having it”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

<a id="topic-2.2.1.6-2"></a>

###### Target organ damage: heart, vasculature, kidneys, brain, and retina

> “Hypertension-related target organ damage describes adverse structural or functional changes in major organ systems, including the heart, vasculature, kidneys, brain, and retina due to hypertension.”
> “Common forms of target organ damage include left ventricular hypertrophy, HF, subclinical and clinical atherosclerosis, CKD (ie, reduced eGFR or albuminuria), and cerebrovascular disease (eg, stroke, dementia, retinopathy).”
> “longitudinal data indicate at least 1 form of hypertension-related target organ damage is present in >50% of individuals with hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The former group was younger, more frequently men, with a longer duration of hypertension and a worse cardiovascular risk profile.”
> “The group included larger proportions of smokers, diabetics, target organ damage (including left ventricular hypertrophy, impaired renal function, and microalbuminuria), and documented cardiovascular disease.”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

<a id="topic-2.2.1.6-3"></a>

###### Acute presentation: hypertensive emergency

> “Hypertensive emergencies are defined as severe elevations in BP (>180/120 mm Hg) associated with evidence of acute target organ damage.”
> “Patients with hypertensive emergencies experience a high in-hospital mortality rate of 10% with a 1-year cardiovascular morbidity and mortality rate of 20% to 30%.”
> “Common forms of acute hypertension-related target organ damage include acute HF/pulmonary edema, neurologic disorders (encephalopathy, ICH, acute ischemic stroke), and AKI, with aortic dissection the least common presentation.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.6-4"></a>

###### Sleep-related symptoms: obstructive sleep apnea

> “Very high proportions (60%−84%) of individuals with RH have sleep apnea.”
> “clinicians should vigorously screen such patients for symptoms of OSA (loud snoring, frequent nocturnal arousals, witnessed apnea, and excessive daytime sleepiness) and have a low threshold for referral for definitive evaluation and treatment.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Snoring, choking, gasping during sleep; daytime sleepiness; resistant hypertension”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.6-5"></a>

###### Electrolyte signs: hypokalemia in primary aldosteronism

> “Spontaneous hypokalemia is present only in 20% to 50% of patients with primary aldosteronism”
> “Although the increased potassium excretion, if prolonged and severe, may cause hypokalemia, hypokalemia is absent in the majority of cases in whom normokalemia has a low negative predictive value for the diagnosis of primary aldosteronism.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis.”
> “Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).”

Source: [Douma et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18539224/)

<a id="topic-2.2.1.6-6"></a>

###### Circadian blood pressure pattern: nocturnal nondipping

> “The normal nocturnal decline in BP is also attenuated in a high proportion (43%−65%) of individuals with RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Moreover, true resistant hypertensives exhibited in a greater proportion a riser pattern (22% versus 18%; P<0.001).”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

<a id="topic-2.2.1.6-7"></a>

###### Paroxysmal symptoms: pheochromocytoma and paraganglioma

> “The prevalence is likely higher in patients referred for RH (eg, up to 4%).”
> “Symptoms include paroxysmal hypertension (which may be sustained in up to 50% of those with high norepinephrine production or orthostatic in epinephrine-predominant tumors) associated with headache, palpitations, pallor, and piloerection”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Usual blood pressure and vascular mortality: one million adults

> “Information was obtained on each of one million adults with no previous vascular disease recorded at baseline in 61 prospective observational studies of blood pressure and mortality.”
> “At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.”

Source: [Lewington et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12493255/)

> “Higher BP is associated with an elevated risk for total CVD, coronary heart disease, HF, aortic and peripheral vascular disease, kidney disease, ischemic and hemorrhagic stroke, dementia, and cognitive impairment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.7-2"></a>

###### Excess risk in resistant hypertension: guideline statements

> “Patients with resistant hypertension are known to have at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death than adults with hypertension without resistance to treatment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.7-3"></a>

###### Excess risk in resistant hypertension: Kaiser Permanente Southern California cohort

> “We sought to compare the risk of end stage renal disease (ESRD), ischemic heart event (IHE), congestive heart failure (CHF), cerebrovascular accident (CVA), and all-cause mortality among 470,386 individuals with resistant and nonresistant hypertension (non-RH).”
> “Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.”
> “The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.7-4"></a>

###### Excess risk in resistant hypertension: incident treated hypertension cohort

> “Following multivariable adjustment including baseline patient demographics, comorbidities, study site, and year of study entry, resistant hypertension was associated with increased risk of adverse CV outcomes (HR 1.47, 95% CI 1.33–1.62, p<0.001).”

Source: [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)

<a id="topic-2.2.1.7-5"></a>

###### Excess risk in uncontrolled and true resistant hypertension

> “Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.”
> “In the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), uncontrolled RH was associated with a 2-fold increased risk of coronary heart disease compared with controlled RH.”
> “BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.”
> “In patients with CKD, RH is associated with higher risk of myocardial infarction, stroke, peripheral arterial disease, heart failure, and all-cause mortality compared with patients without RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.7-6"></a>

###### Excess risk in primary aldosteronism

> “We identified 31 studies including 3838 patients with primary aldosteronism and 9284 patients with essential hypertension.”
> “After a median of 8·8 years (IQR 6·2-10·7) from the diagnosis of hypertension, compared with patients with essential hypertension, patients with primary aldosteronism had an increased risk of stroke (odds ratio [OR] 2·58, 95% CI 1·93-3·45), coronary artery disease (1·77, 1·10-2·83), atrial fibrillation (3·52, 2·06-5·99), and heart failure (2·05, 1·11-3·78).”

Source: [Monticone et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29129575/)

> “Meta-analyses of studies that matched patients with primary aldosteronism to those with primary hypertension showed that primary aldosteronism carries a 2.0-fold increased risk of HF, 2.8-fold increased risk of stroke, 1.7-fold increased risk of coronary artery disease, 4.0-fold increased risk of AF, and increased kidney damage compared with primary hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.7-7"></a>

###### Cardiovascular risk reduction per 5 mm Hg systolic blood pressure: individual participant data meta-analysis

> “Data for 344 716 participants from 48 randomised clinical trials were available for this analysis.”
> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”
> “On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-2.2.1.7-8"></a>

###### Cardiovascular risk reduction per 10 mm Hg systolic blood pressure: trial-level meta-analysis

> “We identified 123 studies with 613,815 participants for the tabular meta-analysis.”
> “Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).”
> “However, the effect on renal failure was not significant (0·95, 0·84-1·07).”
> “There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.”

Source: [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Hypertension

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011

> “We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011.”
> “2501 (4.4%) met criteria for aTRH.”
> “Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4).”
> “In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension.”
> “In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension.”

Source: [Carris et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26084656/)

<a id="topic-2.2.1.8.1-2"></a>

###### Proposed contributors to lower quality of life in treatment-resistant hypertension: review

> “Recent evidence, although limited, suggests that TRH may also adversely affect health-related quality of life (HrQoL) and other patient-reported outcomes.”
> “A number of recent studies focusing on both the general hypertensive population and those with TRH suggest that patient awareness of difficult-to-control blood pressure, chronically elevated blood pressure levels, and the use of aggressive medication regimens with attendant cumulative adverse effects may play significant roles.”

Source: [Carris and Smith (2015)](https://pubmed.ncbi.nlm.nih.gov/26115629/)

<a id="topic-2.2.1.8.1-3"></a>

###### SF-36 and SF-12 scores in hypertension compared with normotension: meta-analysis of 20 studies

> “Most of the 20 studies selected for the systematic review identified lower quality of life in patients with hypertension, but they were very heterogeneous in regard to selection criteria and comparison groups, limiting their external validity.”
> “The meta-analysis identified lower scores in hypertensive patients for physical [-2.43; 95% confidence interval (CI) -4.77 to -0.08] and mental (-1.68; 95% CI -2.14 to -1.23) components.”
> “Quality of life of individuals with hypertension is slightly worse than that of normotensive individuals.”

Source: [Trevisol et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21045726/)

<a id="topic-2.2.1.8.1-4"></a>

###### EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002

> “The nationally representative Medical Expenditure Panel Survey (MEPS) was pooled (2000−2002) to create a data set of 38,678 adults.”

Source: [Sullivan and Ghushchyan (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2634296/)

| ICD-9 condition | Respondents (n) | Unadjusted mean EQ-5D | Median EQ-5D | Adjusted disutility (CLAD regression) |
| --- | --- | --- | --- | --- |
| 401 Essential hypertension | “7085” | “0.789” | “0.816” | “−0.0250” |
| 410 Acute myocardial infarction | “244” | “0.704” | “0.778” | “−0.0409” |
| 414 Other chronic ischemic heart disease | “183” | “0.738” | “0.794” | “−0.0336” |
| 428 Heart failure | “284” | “0.636” | “0.708” | “−0.0635” |
| 436 Cerebrovascular accident | “340” | “0.650” | “0.768” | “−0.0524” |

Source: [Sullivan and Ghushchyan (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2634296/)

<a id="topic-2.2.1.8.1-5"></a>

###### Health state utilities used in the ICER model of aldosterone synthase inhibitors

> “Patients in the hypertension alone state were assigned an age-specific background utility for the US general population, consistent with prior models”
> “For patients occupying more than one event state, a multiplicative approach was used to combine the relevant condition-specific utilities, consistent with standard practice in multi-state cost-effectiveness models.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Utility or disutility |
| --- | --- |
| Hypertension alone | “Age-specific” |
| Acute myocardial infarction, disutility (3 months) | “-0.15” |
| Post-myocardial infarction, disutility | “-0.041” |
| Acute stroke, disutility (3 months) | “-0.19” |
| Post-stroke, disutility | “-0.052” |
| Coronary heart disease, disutility | “-0.034” |
| Heart failure, disutility | “-0.064” |
| End-stage kidney disease, disutility | “-0.170” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.1-6"></a>

###### EQ-5D-5L quality of life in 56 participants with resistant hypertension: RHYME-RCT

> “A total of 56 patients with median age 61.5 [25th–75th percentile: 55.8–69.3] years (21.4% women) were included.”
> “At 12 months, no differences were observed in EQ-5D-5L index (0.81 [0.69–0.89] vs. 0.89 [0.73–1.00]; P = 0.18) and visual analogue scale score on general patient-perceived health (70 [60–80] vs. 70 [60–82]; P = 0.53) between the intervention-arm and the standard-of-care only-arm.”
> “Irrespective of the intervention, independent positive predictors of the percentage adherence were patient age, EQ-5D-5L index score, BMQ-specific necessity score and concern score, whereas the total number of drugs prescribed was a negative predictor.”

Source: [Zeijen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11356742/)

<a id="topic-2.2.1.8.1-7"></a>

###### Treatment burden: patient input on pill burden, copays, and coverage barriers

> “For example, many people living with hypertension report needing to take multiple medications.”
> “While almost all antihypertensive medications have an available generic alternative and cost for individual drugs is rarely a barrier to adherence, pill burden, additive copays for multiple medications, variable tolerance for side effects such as frequent urination with diuretics or edema with calcium channel blockers, and a lack of awareness of the importance of treating hypertension – particularly in people without symptoms – can decrease adherence and persistence to treatment.”
> “We heard that insurance coverage barriers, such as prior authorization and step therapy, can place a high burden on patients and can cause people to abandon treatment.”
> “People living with hypertension expressed hope that new medications would be more effective than older medications, allowing them to decrease the number of medications they need to take to control their blood pressure.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.1-8"></a>

###### Pill burden and nonadherence in resistant hypertension: review

> “Reasons include adverse drug effects, pill burden, drug costs, long duration of treatment, and lack of communication from clinicians about the importance of medication adherence and persistence”
> “Because adherence declines as the number of medications rises and the treatment regimen becomes more complex, poor adherence is a particular problem complicating the treatment of patients with RHT”

Source: [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)

<a id="topic-2.2.1.8.1-9"></a>

###### Number of prescribed antihypertensive drugs and biochemically confirmed nonadherence in 1348 participants

> “We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries.”
> “The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively.”
> “Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence (P<0.001) in the UK and Czech populations, respectively.”
> “We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure-lowering therapy.”

Source: [Gupta et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28461599/)

<a id="topic-2.2.1.8.1-10"></a>

###### Prevalence of medication nonadherence in apparent treatment-resistant hypertension: meta-analysis of 24 studies

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “By using a random effects model, the pooled prevalence of nonadherence was 31.2% (95% confidence interval = 20.2-44.7, I = 99.50) with nonadherence rates ranging from 3.3 to 86.1%.”
> “Findings indicate that medication nonadherence is a significant problem among aTRH patients.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

<a id="topic-2.2.1.8.1-11"></a>

###### Regimen simplification: single-pill compared with free-equivalent combination therapy, systematic review of 44 studies

> “Following screening, 44 studies were included. The majority (18 of 23) of studies measuring adherence showed adherence was significantly improved in patients receiving SPCs versus FECs.”
> “SPC therapy leads to improved adherence and persistence compared with FEC therapy and may lead to better BP control in patients with hypertension.”

Source: [Parati et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33390044/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### National health care expenditures and events associated with hypertension: MEPS 2019

> “Hypertension was associated with $2,759 (95% confidence interval [CI]: $2,039, $3,479) in health care expenditures and 10.3 (95% CI: 9.3, 11.3) health care events, including prescriptions filled, in 2019 per person.”
> “Estimated annual national health care expenditures associated with hypertension were about $219.2 billion in the United States in 2019. This includes $32.5 billion in prescribed medication purchases, $70.2 billion in outpatient services, and $79.4 billion in inpatient services. The number of health care events associated with hypertension was about 817.4 million, including 538.2 million prescribed medication purchases, 168.1 million outpatient visits, 3.5 million inpatient visits, and 6.0 million ED visits”
> “Results from this study indicated that hypertension was associated with more than 10% of the total health care expenditures and events at national level”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585433/)

<a id="topic-2.2.1.8.2-2"></a>

###### Annual costs of high blood pressure: CDC

> “Annual costs associated with high blood pressure were an estimated $219 billion in the United States in”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

<a id="topic-2.2.1.8.2-3"></a>

###### Incremental expenditure for adults with hypertension: MEPS 2003 to 2014

> “Relative to individuals without hypertension, individuals with hypertension had $1920 higher annual adjusted incremental expenditure, 2.5 times the inpatient cost, almost double the outpatient cost, and nearly triple the prescription medication expenditure. Based on the prevalence of hypertension in the United States, the estimated adjusted annual incremental cost is $131 billion per year higher for the hypertensive adult population compared with the nonhypertensive population.”

Source: [Kirkland et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6015342/)

<a id="topic-2.2.1.8.2-4"></a>

###### Direct and indirect cost and hospital, office, and emergency department use: AHA statistics

> “The estimated direct and indirect cost of HBP for 2020 to 2021 (annual average) was $49.0 billion”
> “Estimated US health care expenditures for hypertension in 2016 were $79 (95% CI, $72.6–$86.8) billion. Of 154 health conditions, hypertension ranked 10th in health care expenditures.”
> “From 2011 to 2021, the number of inpatient discharges from short-stay hospitals with HBP as the principal diagnosis increased from 296 253 to 1 311 528. The number of discharges with any listing of HBP increased from 16 112 764 to 17 160 070 in that same time period.”
> “In 2019, 56 795 000 of 1 036 484 000 physician office visits had a primary diagnosis of essential hypertension”
> “There were 779 438 ED discharges with a principal diagnosis of essential hypertension in 2021”

Source: [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)

<a id="topic-2.2.1.8.2-5"></a>

###### US spending on treatment of hypertension by type of care and payer, 2019

| Measure | Treatment of hypertension |
| --- | --- |
| Total 2019 spending, US$ billions (95% CI) | “35.57 (34.9-36.2)” |
| Share of spending in adults older than 65 years, % | “56.7” |
| Inpatient care, % | “0.3” |
| Emergency department, % | “4.5” |
| Ambulatory care, % | “41.8” |
| Prescribed retail pharmaceuticals, % | “39.5” |
| Nursing facility, % | “4.0” |
| Medicare, % | “39.9” |
| Medicaid, % | “14.3” |
| Private insurance, % | “29.3” |
| Out of pocket, % | “16.6” |

Source: [Dieleman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829247/)

<a id="topic-2.2.1.8.2-6"></a>

###### Resource use and costs with uncontrolled compared with controlled blood pressure in apparent treatment-resistant hypertension and stage 3 or 4 CKD: US claims, 3966 patients

> “This retrospective cohort study used linked IQVIA Ambulatory EMR–US and IQVIA PharMetrics Plus claims databases.”
> “Of 3,966 patients with stage 3–4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03–1.36]), ESRD (1.85 [1.44–2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28–1.43]), and outpatient visits (1.12 [1.11–1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741–$13,646] per patient per year).”
> “Total medical costs were driven primarily by outpatient visits (+$6,514) and inpatient hospital admissions (+$3,202).”
> “Similarly, in our sensitivity analysis using a BP threshold of ≥140/90 mm Hg, there were increases in inpatient hospitalizations (HR, 1.26) and outpatient visits (HR, 1.18), and total costs increased by approximately $9,000.”

Source: [Bakris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094384/)

<a id="topic-2.2.1.8.2-7"></a>

###### Outpatient visit frequency in apparent treatment-resistant hypertension: REGARDS linked with Medicare claims

> “We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS study linked with Medicare claims.”
> “Among 4650 participants with hypertension, 468 (10.1%) had UaTRH, 247 (5.3%) had CaTRH, and 3935 (84.6%) had hypertension but did not have aTRH. For hypertension-related visits, those with UaTRH saw primary care physicians and cardiologists more frequently than those without aTRH (mean primary care visits per year: 2.77 vs 2.27, P < .001; cardiologists: 0.50 vs 0.35, P = .014).”
> “Many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.”

Source: [Vemulapalli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8218938/)

<a id="topic-2.2.1.8.2-8"></a>

###### Added expenditure attributed to apparent resistant hypertension: review

> “Compared with nonresistant hypertension, RHT is associated with an added economic burden on both the US health care system and individual patients.”
> “Apparent RHT is estimated to increase US health care expenditures by $11 billion to $18 billion per year over those associated with non-resistant hypertension”
> “Suboptimal adherence to prescribed medications also increases total health care costs”

Source: [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)

<a id="topic-2.2.1.8.2-9"></a>

###### Annual costs of cardiovascular health states used in the ICER model, 2025 US dollars

> “For acute cardiovascular events, a first-cycle cost reflecting acute hospitalization and care was applied in the cycle of the event, followed by ongoing annual costs for the post-event state in subsequent cycles.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Direct medical cost | Productivity cost (modified societal perspective) |
| --- | --- | --- |
| Hypertension (annual) | “$3,211” | Not reported |
| Stroke (acute and annual; annual for productivity) | “$20,442 / $20,697” | “$16,781” |
| Myocardial infarction (acute and annual; annual for productivity) | “$25,832 / $17,106” | “$19,028” |
| Coronary heart disease (annual) | “$13,798” | “$7,092” |
| Heart failure (index hospitalization and annual; annual for productivity) | “$16,671 / $33,890” | “$16,004” |
| End-stage kidney disease (annual) | “$108,953” | “$17,650” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.2-10"></a>

###### Productivity loss associated with hypertension in the United States: review of 27 studies

> “Twenty-seven articles met the inclusion criteria.”
> “Annual absenteeism was estimated to cost more than $11 billion, nationally controlling for sociodemographic characteristics. The annual additional costs per person were estimated at $63 for short-term disability, $72–$330 for absenteeism, and $53–$156 for presenteeism, controlling for participant characteristics; and may be as high as $2362 for absenteeism and presenteeism when considered in combination.”
> “The annual additional time loss per person was estimated as 1.3 days for absenteeism, controlling for common hypertension comorbidities, including stroke and diabetes; and 15.6 days for work and home productivity loss combined, controlling for sociodemographic characteristics.”
> “The loss from absenteeism alone might be more than 20% of the total medical expenditure of hypertension.”

Source: [MacLeod et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9536345/)

<a id="topic-2.2.1.8.2-11"></a>

###### Antihypertensive adherence, medical costs, and disability costs in commercially insured adults: MarketScan 2019

> “We conducted cross‐sectional analyses using MarketScan databases, which included individuals aged 18 to 64 years with noncapitated health insurance plans in 2019.”
> “54.4% adhered to antihypertensives.”
> “Per person, antihypertensive medication adherence was associated with $1441 lower total medical costs, $11 lower sick absence costs, $291 lower short‐term disability costs, and $69 lower long‐term disability costs. Per 1000 individuals, medication adherence was associated with lower health care use, including 200 fewer emergency department visits and 90 fewer inpatient admissions, and productivity‐related outcomes, including 20 fewer sick absence days and 442 fewer short‐term disability days.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11935718/)

<a id="topic-2.2.1.8.2-12"></a>

###### Projected health care costs of cardiovascular risk factors including hypertension through 2050

> “We used nationally representative health, economic, and demographic data to project health care costs attributable to key cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia) and conditions (coronary heart disease, stroke, heart failure, atrial fibrillation) through 2050.”
> “Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion.”

Source: [Kazi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38832515/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Hypertension on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Out-of-pocket share of US spending on treatment of hypertension, 2019

| Payer | Share of 2019 spending on treatment of hypertension, % |
| --- | --- |
| Medicare | “39.9” |
| Medicaid | “14.3” |
| Private insurance | “29.3” |
| Out of pocket | “16.6” |

Source: [Dieleman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829247/)

<a id="topic-2.2.1.8.3-2"></a>

###### Cost-related medication nonadherence among US adults with hypertension: National Health Interview Survey 2017

> “Participants with self-reported hypertension from the 2017 National Health Interview Survey were included (n = 7,498).”
> “Overall, 10.7% reported CRMN, 83.6% reported current antihypertensive medication use, and 67.4% reported normal blood pressure within past 12 months. Adjusted percentages of current antihypertensive medication use (88.6% vs. 82.9%, P < 0.001) and self-reported normal blood pressure (69.8% vs. 59.5%, P = 0.002) were higher among those without CRMN compared with those with CRMN.”
> “Financial barriers to medication adherence persist and impact hypertension management.”

Source: [Fang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32369108/)

<a id="topic-2.2.1.8.3-3"></a>

###### Cost-related medication nonadherence by age, sex, and insurance status: National Health Interview Survey 2019 to 2022

> “This analytical cross-sectional study utilized data from the National Health Interview Survey Sample from 2019 to 2022.”
> “Women aged 18-64 years more likely (adjusted odds ratio (aOR) 1.44; 95% CI 1.18, 1.75) to experience CRN than men. Notably, uninsured individuals in both the 18-64 (aOR 2.21; 95% CI 1.51, 3.25) and ≥ 65 (aOR 5.55; 95% CI 1.36, 22.75) age groups were at increased risk of facing CRN.”
> “To mitigate CRN, health quality strategies like prescribing generics, connecting patients with assistance programs, and implementing policies to reduce out-of-pocket costs are essential.”

Source: [Reddy et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40285540/)

<a id="topic-2.2.1.8.3-4"></a>

###### Additive copays for multiple medications: patient input

> “Clinical inertia, pill burden, additive copays for multiple medications, variable tolerance for side effects, and a lack of awareness of the importance of treating hypertension can make treatment challenging.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.3-5"></a>

###### Caregiver time and cost burden in uncontrolled or resistant hypertension

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Screening for primary aldosteronism with aldosterone and renin: Endocrine Society guideline

> “We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.”
> “The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity.”

Source: [Adler et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40658480/)

<a id="topic-2.2.1.8.4-2"></a>

###### Cost and testing burden of broader primary aldosteronism screening: 2025 AHA/ACC guideline

> “Studies from Australia and Japan suggest that broader screening for primary aldosteronism in individuals with hypertension is cost-effective”
> “Nonetheless, the potential burden of additional testing outside of patients with resistant hypertension to confirm the diagnosis of primary aldosteronism and to determine optimal therapy may be taken into consideration prior to screening.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.8.4-3"></a>

###### Primary aldosteronism testing rates and treatment in 269 010 Veterans with apparent treatment-resistant hypertension

> “Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017”
> “4277 (1.6%) patients who were tested for primary aldosteronism were identified.”
> “Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.”
> “Testing for primary aldosteronism in patients with apparent treatment-resistant hypertension is cost-effective and may substantially improve long-term outcomes”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

<a id="topic-2.2.1.8.4-4"></a>

###### Underdiagnosis, downstream costs, and cost-effectiveness of broader screening: review

> “Fewer than 2% of eligible patients are screened for primary aldosteronism (PA) despite evidence that early detection and targeted therapy are associated with lower cardiovascular and kidney morbidity.”
> “The resulting underdiagnosis not only prolongs exposure to excess aldosterone but also increases healthcare utilization and costs through preventable hospitalizations, procedural interventions, and long-term management of aldosterone-mediated end-organ damage.”
> “In a modeling study focused on patients with apparent treatment resistant hypertension in the U.S., Gaziano et al. assessed the cost-effectiveness of multiple diagnostic strategies and an empiric MRA treatment approach. Screening with ARR followed by confirmatory testing, AVS, and surgical adrenalectomy, when appropriate, were cost-effective, with incremental cost-effectiveness ratios well within commonly accepted thresholds.”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

<a id="topic-2.2.1.8.4-5"></a>

###### Cost-effectiveness of primary aldosteronism screening and subtype diagnosis in resistant hypertension: US decision model

> “At a U.S. WTP threshold of $150,000/QALY and without adjustments in HRQoL for patients with surgically untreated PA, CT/AVS strategy is the cost-effective choice with an ICER of $82,000/QALY”
> “ICERs for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective.”
> “Integrating differential patient-reported health-related quality of life adjustments for patients with PA, ICERs for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained.”
> “CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with resistant hypertension.”

Source: [Lubitz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4651757/)

| Test or procedure (CPT or DRG codes as printed) | Base-case cost |
| --- | --- |
| Screening aldosterone to renin ratio (CPT 82088, 84244, 84132) | “$93” |
| Confirmatory saline infusion testing (CPT 96365, 93666) | “$141” |
| Abdominal CT (CPT 74170) | “$329” |
| Adrenal venous sampling (CPT 75893, 36500) | “$2,645” |
| Adrenalectomy, surgery and anesthesia (CPT 60650, 00866) | “$3,054” |
| One year cost of spironolactone | “$158” |

Source: [Lubitz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4651757/)

<a id="topic-2.2.1.8.4-6"></a>

###### Medicare fee schedule costs of primary aldosteronism work-up and therapeutic drug monitoring-guided screening in resistant hypertension

> “Cost of therapeutic drug monitoring for three drugs=3×$25=$75”
> “Cost of screening for primary aldosteronism (PA)=$30 for plasma renin activity+$56 for serum aldosterone=$86”
> “Cost of adrenal vein sampling=$2328.73”
> “Cost of computed tomographic scan of adrenal glands=$588.53”
> “A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM‐guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy.”

Source: [Velasco et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4562815/)

<a id="topic-2.2.1.8.4-7"></a>

###### Cost-effectiveness of primary aldosteronism screening in all adults with hypertension from age 40: Australian Markov model

> “A Markov model was used to estimate the cost-effectiveness of screening for primary aldosteronism in treatment and disease (cardiovascular disease and stroke) naive hypertensive patients.”
> “The results from this study demonstrated that screening all hypertensive patients for primary aldosteronism from age 40 is cost-effective.”

Source: [Woode et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37466447/)

<a id="topic-2.2.1.8.4-8"></a>

###### Care-pathway cost of investigating secondary and apparent treatment-resistant hypertension in a specialist clinic: Ireland

> “Sixty-five patients originally recruited for a study of medication adherence in hypertension were included in the sample.”
> “The total care-pathway cost per patient, taking into account clinic visits, clinical reviews, investigations and MDT discussion, was estimated to be €3277, on average. For the patient subgroups, the average cost was €5644 for patients diagnosed with primary aldosteronism and €1446 for patients diagnosed with essential hypertension.”

Source: [Rabbitt et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38009268/)

<a id="topic-2.2.1.8.4-9"></a>

###### Medicare coverage of ambulatory blood pressure monitoring

> “For dates of service on and after July 2, 2019, the Centers for Medicare & Medicaid Services (CMS) believes that the evidence is sufficient to determine that ABPM is reasonable and necessary for the diagnosis of hypertension in Medicare beneficiaries under the following circumstances”
> “For eligible patients, ABPM is covered once per year.”
> “Coverage of other indications for ABPM not indicated above are at the discretion of the Medicare Administrative Contractors.”

Source: [CMS National Coverage Determination 20.19, ambulatory blood pressure monitoring (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=254)

<a id="topic-2.2.1.8.4-10"></a>

###### Cost-effectiveness of clinic, home, and ambulatory blood pressure measurement for diagnosis: US model

> “We compared quality-adjusted life-years and lifetime costs ($US 2017 from the US healthcare perspective) associated with clinic BP measurement, home BP monitoring, and ABPM under 2 scenarios: positive and negative initial screen.”
> “In the screen-positive scenario, ABPM was the dominant strategy among all age and sex groups. Compared with clinic BP measurement, ABPM was associated with cost-savings ranging from $77 (women 80 years of age) to $5013 (women 21 years of age).”
> “ABPM is recommended as the diagnostic strategy of choice for most adults in primary care settings regardless of initial screening results.”

Source: [Beyhaghi and Viera (2019)](https://pubmed.ncbi.nlm.nih.gov/30571548/)

<a id="topic-2.2.1.8.4-11"></a>

###### Practicality and availability of home and ambulatory blood pressure monitoring: 2025 AHA/ACC guideline

> “Further, HBPM is often a more practical approach in clinical practice than ABPM and may be more reproducible and accessible, supporting its use for longitudinal management and titration of BP-lowering medication.”
> “Additional studies comparing home and ambulatory BP measurements in estimating CVD risk are greatly needed to reduce treatment disparities due to lack of availability of ABPM to all populations.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.8.4-12"></a>

###### Costs and cost-effectiveness of self-measured blood pressure monitoring: Community Guide systematic review of 22 studies

> “The literature search from database inception to March 2015 identified 22 studies for inclusion with three types of interventions: SMBP used alone, SMBP with additional support, and SMBP within team-based care (TBC).”
> “Median costs of intervention were $60 and $174 per person for SMBP alone and SMBP with additional support, respectively, and $732 per person per year for SMBP within TBC.”
> “SMBP monitoring interventions with additional support or within TBC are cost effective. Cost effectiveness of SMBP used alone could not be determined.”

Source: [Jacob et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5657494/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Lifestyle and Dietary Interventions

<a id="topic-2.2.2.1.1-1"></a>

###### Lifestyle recommendation for all adults: 2025 AHA/ACC guideline

> “For all adults, lifestyle changes, including maintaining or achieving a healthy weight, following a heart-healthy eating pattern (such as DASH [Dietary Approaches to Stop Hypertension]), reducing sodium intake, increasing dietary potassium intake, adopting a moderate physical activity program, managing stress, and reducing or eliminating alcohol intake are strongly recommended to prevent or treat elevated blood pressure and hypertension.”
> “Once patients have been diagnosed with hypertension, specific lifestyle and nonpharmacological strategies can lower BP, slow progression of BP elevation, reduce the amount of medication needed to control BP, and prevent CVD events and mortality.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-2"></a>

###### Expected blood pressure reductions by intervention: 2025 AHA/ACC guideline

> “Aim for sustained ≥5% reduction in body weight or ≥3 kg/m2 reduction in BMI; expect about 1 mm Hg reduction for every 1-kg reduction in body weight”
> “Reduction in BP with the DASH eating plan varies across trials, from 1 to 13 mm Hg for SBP and from 1 to 10 mm Hg for DBP.”
> “On average, low-sodium (≤1500-2300 mg/d) versus high-sodium (≥4500 mg/d) diets safely result in BP reductions of approximately 3/2 mm Hg (systolic/diastolic) in normotensive and 7/3 mm Hg in hypertensive individuals.”
> “Aerobic exercise reduces SBP on average by 4 to 7/3 to 4 mm Hg, with a slightly larger effect in patients with versus without hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-3"></a>

###### Potassium-based salt substitutes: 2025 AHA/ACC guideline

> “COR 2a: In adults with or without hypertension, potassium-based salt substitutes can be useful to prevent or treat elevated BP and hypertension, particularly for patients in whom salt intake is related mostly to food preparation or flavoring at home, except in the presence of CKD or use of drugs that reduce potassium excretion where additional monitoring is probably indicated.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-4"></a>

###### Sodium target and lifestyle intervention in resistant hypertension: 2024 ESC guideline

> “It is recommended to restrict total dietary sodium intake to approximately 2 g/day or less (equivalent to approximately 5 g or about a teaspoon of salt per day).”
> “The Treating Resistant Hypertension Using Lifestyle Modification to Promote Health (TRIUMPH) trial demonstrated significant clinic and ambulatory BP reductions in patients with resistant hypertension participating in a 4-month lifestyle intervention comprising diet and exercise interventions delivered within a cardiac rehabilitation programme.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.1-5"></a>

###### Diet and exercise program in resistant hypertension: TRIUMPH randomized trial

> “One hundred forty patients with RH (mean age 63 years; 48% female; 59% Black; 31% with diabetes; 21% with chronic kidney disease) were randomly assigned to a 4-month program of lifestyle modification (C-LIFE) including dietary counseling, behavioral weight management, and exercise; or a single counseling session providing standardized education and physician advice (SEPA).”
> “Between-group comparisons revealed that the reduction in clinic SBP was greater in C-LIFE (−12.5 [95% CI: −14.9, −10.2] mm Hg) compared with SEPA”
> “24-hour ambulatory SBP also was reduced in C-LIFE (−7.0 [95% CI: −8.5, −4.0] mm Hg), with no change in SEPA (−0.3 [95% CI: −4.0, 3.4] mm Hg) (P = .001).”

Source: [Blumenthal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8511053/)

<a id="topic-2.2.2.1.1-6"></a>

###### Dietary sodium restriction in resistant hypertension: crossover trial

> “Twelve subjects with resistant hypertension entered into a randomized, cross-over evaluation of low (50 mmol/24-hr × 7 days) and high sodium diets (250 mmol/24-hr × 7 days) separated by a 2-week washout period.”
> “Low- compared to high-salt diet decreased office systolic and diastolic blood pressure by 22.7 and 9.1 mm Hg, respectively.”

Source: [Pimenta et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2771382/)

<a id="topic-2.2.2.1.1-7"></a>

###### Sodium reduction combined with the DASH diet: DASH-Sodium trial

> “A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet.”
> “As compared with the control diet with a high sodium level, the DASH diet with a low sodium level led to a mean systolic blood pressure that was 7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension.”

Source: [Sacks et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11136953/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Thiazide-type Diuretics, Renin-Angiotensin System Inhibitors, and Calcium Channel Blockers

<a id="topic-2.2.2.1.2-1"></a>

###### First-line drug classes: 2025 AHA/ACC guideline

> “Strong RCT evidence supports 4 classes of first-line agents compared with placebo (thiazide-type diuretics, long-acting dihydropyridine CCB, and ACEi and ARB) due to their favorable profiles for BP lowering, CVD prevention, and tolerability.”
> “While there are subtle differences among thiazide-type diuretics, long-acting dihydropyridine CCB, and ACEi and ARB, the general pattern indicates a similar effect in preventing CVD.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.2-2"></a>

###### Initial combination therapy and single-pill combinations: 2025 AHA/ACC guideline

> “For all adults with stage 2 hypertension, the initiation of antihypertensive drug therapy with 2 first-line agents of different classes in a single-pill, fixed-dose combination is preferred over 2 separate pills to improve adherence and reduce time to achieve blood pressure control.”
> “Initial combination therapy is recommended for stage 2 hypertension and some high-risk patients with stage 1 hypertension (eg, non-Hispanic Black adults, ASCVD risk >7.5%) using 2 agents from different classes, preferably in an SPC to improve adherence and BP control”
> “Available RCT evidence supports using an RAS blocker with either a thiazide-type diuretic or a dihydropyridine CCB as initial therapy.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.2-3"></a>

###### Three-drug regimen before a diagnosis of resistant hypertension: 2025 AHA/ACC guideline

> “Resistant hypertension is defined as BP above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses or BP at goal but requiring ≥4 medications (Figure 8).”
> “Antihypertensive drug therapy should start with a combination of an ACEi or ARB, a CCB, and a diuretic.”
> “Replacing thiazide-type diuretics (eg, HCTZ or bendroflumethiazide) with thiazide-like diuretics (eg, chlorthalidone and indapamide) may offer additional BP reduction”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.2-4"></a>

###### Chlorthalidone and hydrochlorothiazide: 2025 AHA/ACC guideline

> “Chlorthalidone has a longer half-life and is more potent than hydrochlorothiazide on a mg-to-mg basis.”
> “In a large pragmatic RCT comparing HCTZ 25 mg to chlorthalidone 12.5 mg, switching from HCTZ to chlorthalidone did not lower the rates of MACE.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.2-5"></a>

###### First-line drug classes and triple combination: 2024 ESC guideline

> “The major four drug classes (ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide or thiazide-like diuretics) are recommended as first-line BP-lowering medications, either alone or in combination.”
> “For most hypertensive patients, a single-pill combination, initially containing two of these major drug classes, and initially at low dose, is recommended.”
> “When BP is still uncontrolled under maximally tolerated triple-combination (RAS blocker, CCB, and diuretic) therapy, and after adherence is assessed, the patient should be considered resistant and referred to an expert centre for appropriate work-up (see Section 7.5).”
> “BP-lowering treatment of resistant hypertension with single-pill combinations is recommended to reduce the pill burden, thereby increasing drug adherence and persistence.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.2-6"></a>

###### Chlorthalidone in stage 4 chronic kidney disease: CLICK trial

> “A total of 160 patients underwent randomization, of whom 121 (76%) had diabetes mellitus and 96 (60%) were receiving loop diuretics.”
> “The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg (95% confidence interval [CI], −13.9 to −8.1) in the chlorthalidone group and −0.5 mm Hg (95% CI, −3.5 to 2.5) in the placebo group. The between-group difference was −10.5 mm Hg (95% CI, −14.6 to −6.4) (P<0.001).”
> “Hypokalemia, reversible increases in serum creatinine level, hyperglycemia, dizziness, and hyperuricemia occurred more frequently in the chlorthalidone group than in the placebo group.”

Source: [Agarwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9119310/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Steroidal Mineralocorticoid Receptor Antagonists

<a id="topic-2.2.2.1.3-1"></a>

###### Spironolactone as the fourth drug: 2025 AHA/ACC guideline

> “RCTs have shown that addition of spironolactone (25-50 mg/day) as the fourth drug reduced home and 24-hour SBP by 6.6 to 8.7 mm Hg when compared with placebo in patients with resistant hypertension and eGFR ≥45 mL/min/1.73 m2.”
> “Nevertheless, 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone due to hyperkalemia or antiandrogenic side effects.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.3-2"></a>

###### Eplerenone as an alternative: 2025 AHA/ACC guideline

> “Eplerenone, a more selective steroidal MRA that avoids the antiandrogenic side effects but may cause hyperkalemia, is a potential alternative to spironolactone, but RCTs have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily when compared with placebo, and effective treatment may require higher dosages.”
> “Use of nonsteroidal MRA for treating resistant hypertension in patients with moderate to advanced CKD has not been tested in a clinical trial but may be considered in selected patients with close monitoring of serum potassium.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.3-3"></a>

###### Aldosterone antagonist dosing and cautions: 2025 AHA/ACC guideline drug table

> “These are preferred agents in primary aldosteronism and resistant hypertension. Spironolactone is associated with greater risk of gynecomastia and impotence compared with eplerenone. Demonstrated efficacy as fourth-agent add-on therapy for resistant hypertension. Avoid use with K+ supplements, other K+-sparing diuretics, or significant renal dysfunction (eg, GFR <45 mL/min). Eplerenone often requires twice-daily dosing for adequate BP lowering. Avoid use in pregnancy.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.3-4"></a>

###### Spironolactone and eplerenone in resistant hypertension: 2024 ESC guideline

> “Most patients with resistant hypertension require the addition of non-first-line BP-lowering drugs (Figure 22). Of these, low-dose spironolactone (25–50 mg daily) should be considered first.”
> “The use of spironolactone can be precluded by limited tolerability due to anti-androgenic side effects resulting in breast tenderness or gynaecomastia (in about 6%), impotence in men, and menstrual irregularities in women.”
> “Therefore, spironolactone should be restricted to patients with an eGFR of ≥30 mL/min/1.73 m2 and a plasma potassium concentration of ≤4.5 mmol/L.”
> “If spironolactone is not tolerated due to anti-androgen side effects, eplerenone may be used. If eplerenone is used, higher doses (i.e. 50–200 mg daily) and twice-daily dosing may be necessary to achieve a BP-lowering effect.”
> “Of note, eplerenone is not licensed for hypertension treatment in many countries.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.3-5"></a>

###### Spironolactone as fourth-line treatment: 2023 ESH guideline

> “In patients with true resistant hypertension, the fourth line treatment should include the MRA spironolactone, based on the evidence of its efficacy in the PATHWAY-2 trial”
> “Lack of outcome data and the risk of MRA-induced hyperkalemia and other side effects have restricted the use of MRA in the treatment of hypertension, except in specific conditions such as hyperaldosteronism or resistant hypertension.”
> “Not all patients will be able to tolerate spironolactone because of its antiandrogenic side effects resulting in breast tenderness, gynecomastia and sexual impotence in men, and menstrual irregularities in women.”
> “The other steroidal MRA, eplerenone, has lesser potential to interfere with progesterone or androgen receptors and can, thus, be used alternatively to lower BP, but it is less potent than spironolactone”
> “Only 9.0% of patients with apparent resistant hypertension were treated with an MRA in a survey carried out in the USA”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.3-6"></a>

###### Spironolactone versus placebo, bisoprolol, and doxazosin: PATHWAY-2 trial

> “Patients rotated, in a preassigned, randomised order, through 12 weeks of once daily treatment with each of spironolactone (25–50 mg), bisoprolol (5–10 mg), doxazosin modified release (4–8 mg), and placebo, in addition to their baseline blood pressure drugs.”
> “The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001), superior to the mean of the other two active treatments (doxazosin and bisoprolol; −4·26 [–5·13 to −3·38]; p<0·0001), and superior when compared with the individual treatments; versus doxazosin (–4·03 [–5·04 to −3·02]; p<0·0001) and versus bisoprolol (–4·48 [–5·50 to −3·46]; p<0·0001).”
> “58% of patients had their blood pressure controlled with spironolactone, which was superior to rates for other treatments.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

<a id="topic-2.2.2.1.3-7"></a>

###### Spironolactone safety and population limits: PATHWAY-2 trial

> “Notably, discontinuations due to renal impairment, hyperkalaemia, and gynaecomastia were not increased with spironolactone relative to other treatments and placebo.”
> “Only six (2%) of 285 patients exposed to spironolactone developed a serum potassium on a single occasion greater than 6·0 mmol/L, with a maximum of 6·5 mmol/L.”
> “Our study excluded patients with an eGFR less than 45 mL/min, as have previous studies, thus there are no data on the safety profile of spironolactone in patients with resistant hypertension and an eGFR less than 45 mL/min.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

<a id="topic-2.2.2.1.3-8"></a>

###### Aldosterone antagonists versus beta-blockers as fourth agents: claims cohort

> “We identified 80 598 patients with RH (mean age: 61 years, 51% males), of which 6626 initiated AA and 73 972 initiated BB as the fourth antihypertensive agent.”
> “Among patients with RH, initiation of AA as a fourth-line antihypertensive agent did not significantly reduce major adverse cardiovascular event risk relative to BB initiation (aHR, 0.77 [95% CI, 0.50-1.19]) but did substantially increase the risk of hyperkalemia (aHR, 3.86 [95% CI, 2.78-5.34]), gynecomastia (aHR, 9.51 [95% CI, 5.69-15.89]), and kidney function deterioration (aHR, 1.63 [95% CI, 1.34-1.99]).”

Source: [Desai et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35880517/)

<a id="topic-2.2.2.1.3-9"></a>

###### Spironolactone prescribing information: hypertension indication and dosing

> “ALDACTONE is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in”
> “patients who are not adequately controlled on other agents.”
> “Doses greater than 100 mg/day generally”
> “do not provide additional reductions in blood pressure.”

Source: [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf)

<a id="topic-2.2.2.1.3-10"></a>

###### Spironolactone prescribing information: hyperkalemia and gynecomastia

> “ALDACTONE can cause hyperkalemia. This risk is increased by impaired renal function or concomitant”
> “Monitor serum potassium within 1 week of initiation or titration of ALDACTONE and regularly thereafter.”
> “ALDACTONE can cause gynecomastia. In RALES, patients with heart failure treated with a mean dose of”
> “26 mg of spironolactone once daily, about 9% of the male subjects developed gynecomastia.”

Source: [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf)

<a id="topic-2.2.2.1.3-11"></a>

###### Eplerenone prescribing information: hypertension indication, dosing, and contraindications

> “INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure.”
> “The recommended starting dose of INSPRA is 50 mg administered once daily. The full”
> “pressure response to 50 mg once daily increase the dosage of INSPRA to 50 mg twice daily.”
> “INSPRA is contraindicated for the treatment of hypertension in patients with:”
> “type 2 diabetes with microalbuminuria,”
> “creatinine clearance <50 mL/min, or”
> “Gynecomastia and abnormal vaginal bleeding were reported with INSPRA but not with placebo.”

Source: [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf)

<a id="topic-2.2.2.1.3-12"></a>

###### Comparators for aldosterone synthase inhibitors and hyperkalemia rates: ICER evidence report

> “typical choices for the next agent to add to a patient’s regimen would be spironolactone, eplerenone, or amiloride.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Drug and arm | Participants (n) | Hyperkalemia at 12 weeks (%) |
| --- | --- | --- |
| Spironolactone 15 to 50 mg | “2748” | “17.5” |
| Placebo (spironolactone studies) | “2760” | “7.5” |
| Eplerenone 25 to 50 mg | “5282” | “5” |
| Placebo (eplerenone studies) | “5275” | “2.6” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.3-13"></a>

###### Generic spironolactone and eplerenone costs: ICER evidence report

| Drug | WAC per dose | Net price per year |
| --- | --- | --- |
| Spironolactone 25 mg | “$0.117” | “$43” |
| Spironolactone 100 mg | “$0.4683” | “$171” |
| Eplerenone 50 mg | “$1.3997” | “$511” |
| Eplerenone 100 mg | “$2.793” | “$1,022” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Epithelial Sodium Channel Blockers

<a id="topic-2.2.2.1.4-1"></a>

###### Amiloride when mineralocorticoid receptor antagonists are not tolerated: 2025 AHA/ACC guideline

> “When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10-20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension.”
> “As monotherapy, these agents are minimally effective antihypertensive agents. Combination therapy of a potassium-sparing diuretic with a thiazide-type diuretic can be considered in patients with hypokalemia on thiazide-type diuretic monotherapy. Avoid use in patients with significant CKD (eg, GFR <45 mL/min).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.4-2"></a>

###### Amiloride as an alternative to spironolactone: 2024 ESC guideline

> “Amiloride and clonidine have data suggesting they are as effective as spironolactone for BP lowering, though they lack outcomes data.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.4-3"></a>

###### Amiloride dosing and availability: 2023 ESH guideline

> “Alternative drugs can be amiloride, to be used at high dosages (10– 20 mg per day), which was as effective as spironolactone (25– 50 mg per day) in reducing BP in an open-label extension period of the PATHWAY-2 trial”
> “However, this can lead to an increased pill burden as the marketed dose of amiloride is only 5 mg, and the drug is not available as a single agent but only in combinations (usually 5 mg) in many countries.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.4-4"></a>

###### Amiloride open-label runout: PATHWAY-2 mechanisms substudy

> “assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week open-label runout phase (substudy 3).”
> “Amiloride (10 mg once daily) reduced clinic systolic blood pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.1.4-5"></a>

###### Amiloride versus spironolactone: randomized noninferiority trial

> “Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.”
> “Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.”
> “At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone.”
> “One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

<a id="topic-2.2.2.1.4-6"></a>

###### Amiloride trial limitations: dose and kidney function

> “First, we did not compare the efficacy of higher doses of spironolactone (50 mg vs 20 mg), as used in the PATHWAY-2 trial.”
> “Second, we excluded participants with an estimated glomerular filtration rate of less than 50 mL/min/1.73 m2; hence, our results may not be generalizable to patients with chronic kidney disease.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

<a id="topic-2.2.2.1.4-7"></a>

###### Amiloride hyperkalemia warning: ICER evidence report

> “While rates associated with amiloride treatment were unavailable, amiloride has an FDA boxed warning for hyperkalemia, either alone or in combination with hydrochlorothiazide.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.4-8"></a>

###### Generic amiloride costs: ICER evidence report

| Drug | WAC per dose | Net price per year |
| --- | --- | --- |
| Amiloride 5 mg | “$0.5627” | “$206” |
| Amiloride 10 mg | “$1.1253” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Aldosterone Synthase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### Class: a new mechanism developed to treat hypertension

> “A new class of medications called aldosterone synthase inhibitors (ASI), which decrease production of aldosterone, has been developed to treat hypertension.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Inhibition of aldosterone synthase by baxdrostat decreases plasma aldosterone concentrations, thereby reducing blood pressure.”
> “Baxdrostat has a higher potency and selectivity for aldosterone synthase compared to the closely related enzyme 11β-hydroxylase (final enzyme in cortisol synthesis).”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Baxdrostat (BAXFENDY): the first approved aldosterone synthase inhibitor

> “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
> “The recommended dosage of BAXFENDY is 2 mg orally once daily.”
> “Initial U.S. Approval: 2026”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure.”

Source: [AstraZeneca press release, Baxfendy EU CHMP opinion (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html)

<a id="topic-2.2.2.1.5-3"></a>

###### Baxdrostat: BaxHTN, uncontrolled or resistant hypertension

> “This multinational, randomized, double-blind, placebo-controlled phase 3 trial recruited participants with seated office systolic blood pressure (seated-SBP) ≥140 mmHg and <170 mmHg, despite stable treatment with 2 (uncontrolled hypertension) or ≥3 (resistant hypertension) antihypertensive medications, including a diuretic.”
> “At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8).”

Source: [Flack et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618089/)

<a id="topic-2.2.2.1.5-4"></a>

###### Baxdrostat: Bax24, resistant hypertension

> “Following a 2-week placebo run-in period, patients with 24 h ambulatory SBP ≥130 mm Hg were randomly assigned (1:1) to receive 2 mg baxdrostat or placebo orally once daily for 12 weeks, in addition to background therapy (stratified by baseline ambulatory SBP <140 mm Hg or ≥140 mm Hg).”
> “Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-2.2.2.1.5-5"></a>

###### Baxdrostat: chronic kidney disease with uncontrolled hypertension

> “Baxdrostat showed placebo-corrected reduction in systolic BP of –8.1 (95% confidence interval, –13.4 to –2.8) mm Hg, P = 0.003.”

Source: [Dwyer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12889919/)

<a id="topic-2.2.2.1.5-6"></a>

###### Lorundrostat: investigational aldosterone synthase inhibitor under FDA review

> “Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone.”
> “Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.”
> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.2.2.1.5-7"></a>

###### Vicadrostat: investigational, without a hypertension trial in its phase 3 set

> “In partnership with the University of Oxford, EASi-KIDNEY looked at whether vicadrostat (BI 690517), an investigational compound, in combination with empagliflozin, which has been on the market since 2014, versus empagliflozin alone, could slow kidney disease progression and reduce cardiovascular risk in people with chronic kidney disease.”
> “After a comprehensive benefit-risk assessment of the available data from the study, the company concluded that accumulating trial data did not support a meaningful expectation of clinical benefit in the EASi-KIDNEY chronic kidney disease population for the primary composite endpoint.”
> “EASi program contains three ongoing phase III studies: EASi-HF Preserved, EASi-HF-Reduced and EASi-PROTKT”

Source: [Boehringer Ingelheim press release, EASi-KIDNEY update (2026)](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial)

<a id="topic-2.2.2.1.5-8"></a>

###### Class effect on blood pressure and electrolytes across randomized trials

> “ASI reduced systolic blood pressure (SBP) (MD: –6.7 mm Hg; CrI: −8.78, −4.59; τ2 3.24), diastolic blood pressure (MD: -2.09 mm Hg; CrI: −3.68, −0.44; τ2 1.44), and hypertensive urgency (OR: 0.36; CrI: 0.13, 0.90; τ2 0.07) compared with placebo.”
> “Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.”

Source: [Queiroga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13100762/)

<a id="topic-2.2.2.1.5-9"></a>

###### Long-term follow-up available for the class

> “The longest available follow-up data for lorundrostat is 12 weeks”
> “Despite effective blood pressure lowering, questions remain about the long-term effects of ASIs, as well as their impact on patient-important outcomes and their efficacy and safety in key subgroups (e.g., advanced chronic kidney disease).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Rasmussen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12281267/); [Judge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12209857/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Endothelin Receptor Antagonists

<a id="topic-2.2.2.1.6-1"></a>

###### Aprocitentan: mechanism of action

> “Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ETA and ETB receptors.”
> “In hypertension, ET-1 can cause endothelial dysfunction, vascular hypertrophy and remodeling, sympathetic activation, and increased aldosterone synthesis.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Aprocitentan (TRYVIO): indication, dosage, and boxed warning

> “TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs.”
> “The recommended dosage of TRYVIO is 12.5 mg orally once daily.”
> “TRYVIO is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.”
> “Initiation of TRYVIO is not recommended in patients with severe anemia.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### Aprocitentan: PRECISION trial in resistant hypertension

> “Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic.”
> “The least square mean (SE) change in office systolic blood pressure at 4 weeks was -15·3 (SE 0·9) mm Hg for aprocitentan 12·5 mg, -15·2 (0·9) mm Hg for aprocitentan 25 mg, and -11·5 (0·9) mm Hg for placebo, for a difference versus placebo of -3·8 (1·3) mm Hg (97·5% CI -6·8 to -0·8, p=0·0042) and -3·7 (1·3) mm Hg (-6·7 to -0·8; p=0·0046), respectively.”
> “The respective difference for 24 h ambulatory systolic blood pressure was -4·2 mm Hg (95% CI -6·2 to -2·1) and -5·9 mm Hg (-7·9 to -3·8).”
> “After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5·8 mm Hg, 95% CI 3·7 to 7·9, p<0·0001).”
> “The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12·5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively.”

Source: [Schlaich et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36356632/)

<a id="topic-2.2.2.1.6-4"></a>

###### Aprocitentan: onset of effect and dose in the prescribing information

> “Most of the BP-lowering effect occurred within the first two weeks of treatment with TRYVIO.”
> “The 25 mg dose has not demonstrated a meaningful improvement in blood pressure reduction as compared to the 12.5 mg dose and had an increased risk of edema/fluid retention”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.2.2.1.6-5"></a>

###### Aprocitentan: position in the 2025 AHA/ACC guideline

> “Aprocitentan, a dual endothelin A and B receptor antagonist, was shown to reduce 24-hour ambulatory SBP by 4 to 6 mm Hg compared with placebo in adults with resistant hypertension when added to a CCB, RAS inhibitor, and HCTZ.”
> “Aprocitentan has not been directly compared with spironolactone in the treatment of resistant hypertension”
> “Associated with mild-to-moderate fluid retention usually occurring within the first 4-6 wks of therapy. Indicated as add-on therapy for patients whose BP is not adequately controlled on other antihypertensive medications. Avoid use in pregnancy.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.6-6"></a>

###### Aprocitentan: REMS removed in April 2025

> “The REMS for Tryvio was originally approved on March 19, 2024, and the most recent REMS modification was approved on December 9, 2024.”
> “Elements to Assure Safe Use: We have determined that elements to assure safe use are no longer necessary based on an evaluation of human fetal outcomes reported from 2001 to 2024 after exposure to a drug in the endothelin receptor antagonist (ERA) pharmacologic class.”
> “Therefore, because the elements to assure safe use and the implementation system are no longer necessary to ensure the benefits of the drug outweigh the risk, and to minimize the burden on the healthcare system of complying with a REMS, a REMS is no longer required for Tryvio.”

Source: [FDA NDA 217686 supplement approval letter (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217686Orig1s004ltr.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Aprocitentan: commercial availability and specialist-focused launch

> “Aprocitentan is approved as TRYVIO® in the US for the treatment of systemic hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs, and has been commercially available since October 2024.”
> “Idorsia plans a focused specialty-driven approach centered initially on hypertension centers, nephrologists, and other specialists treating patients with resistant and difficult-to-control hypertension.”

Source: [Idorsia press release, aprocitentan commercialization partnership (2026)](https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3793976)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Beta-blockers, Alpha-blockers, Central Sympatholytics, and Direct Vasodilators

<a id="topic-2.2.2.1.7-1"></a>

###### Fourth- and fifth-line alternatives: 2025 AHA/ACC guideline

> “Other alternative fourth- and fifth-line drug therapies include BBs, alpha blockers, central sympatholytic drugs, and direct vasodilators.”
> “However, direct vasodilators such as hydralazine and minoxidil should be used in combination with a BB and a loop diuretic given their effects on sympathetic tone, sodium reabsorption, and fluid retention.”
> “The reduction in BP was greater than with addition of doxazosin or bisoprolol.”
> “The magnitude of reduction in 24-hour systolic and diastolic BP was greater with spironolactone than clonidine in a separate clinical trial.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-2"></a>

###### Beta-blockers as secondary agents: 2025 AHA/ACC guideline

> “All other antihypertensive agents are considered secondary. BBs were less effective than first-line antihypertensive classes in preventing strokes and had a less favorable side effect profile; therefore, they should be reserved for adults with compelling indications.”
> “Beta blockers are not recommended as first-line agents unless the patient has CHD or HF.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-3"></a>

###### Alpha-1 blockers, central agents, and direct vasodilators: 2025 AHA/ACC guideline drug table

> “These are associated with orthostatic hypotension, especially in older adults with a greater BP drop with first dose effect. These may be considered a second-line agent in patients with symptomatic benign prostatic hypertrophy.”
> “These are generally reserved as last-line choices because of significant CNS adverse effects, especially in older adults. Avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis.”
> “These are associated with sodium and water retention and reflex tachycardia and should be used with a diuretic and beta blocker. Hydralazine is associated with a drug-induced lupus-like syndrome at higher doses. Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-4"></a>

###### Order of alternative agents: 2024 ESC guideline

> “An alternative to MRA as fourth-line treatment for BP lowering is the use of beta-blockers for persons who do not already have a compelling indication. A vasodilating beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a beta-blocker is chosen.”
> “Only thereafter should hydralazine, other potassium-sparing diuretics (amiloride and triamterene), centrally acting BP-lowering medications, or alpha-blockers be considered. Given multiple side-effects, minoxidil should only be considered if all other pharmacological agents prove ineffective in resistant hypertension.”
> “When not already prescribed for a compelling indication, beta-blockers should be considered in the treatment of resistant hypertension, though their BP-lowering effects appear to be less potent than spironolactone in the setting of resistant hypertension.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.7-5"></a>

###### Alternatives when mineralocorticoid receptor antagonists are not tolerated: 2023 ESH guideline

> “When spironolactone and other MRAs are not tolerated or contraindicated (i.e. in CKD stage 4, eGFR <30 ml/min), bisoprolol (5– 10 mg/day), doxazosin extended release (4– 8 mg/day) or a centrally acting agent such as the alpha-adrenergic receptor agonists (clonidine, 0.1– 0.3 mg twice a day)”
> “However, bisoprolol and doxazosin reduced BP less effectively than spironolactone in the PATHWAY-2 trial”
> “Powerful vasodilators, such as hydralazine and minoxidil were occasionally used in the past, but they have been now virtually abandoned because of their association with serious side effects.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.7-6"></a>

###### Spironolactone versus clonidine as the fourth drug: ReHOT trial

> “Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5-50 mg QD) or clonidine (0.1-0.3 mg BID).”
> “Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).”
> “However, spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.”

Source: [Krieger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29463627/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Renal Denervation

<a id="topic-2.2.2.1.8-1"></a>

###### FDA approval: Symplicity Spyral radiofrequency system

> “The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “Decision Date 11/17/2023”

Source: [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026)

<a id="topic-2.2.2.1.8-2"></a>

###### FDA approval: Paradise ultrasound system

> “The Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “Decision Date 11/07/2023”

Source: [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023)

<a id="topic-2.2.2.1.8-3"></a>

###### Medicare coverage with evidence development: CMS national coverage decision

> “The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.”
> “(a) Diagnosis of uncontrolled hypertension (≥ 140 mm Hg systolic blood pressure and > 90 mm Hg diastolic blood pressure) despite active management by a clinician with primary responsibility for blood pressure management.”
> “(c) On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.”
> “At a minimum, patients must be screened for primary aldosteronism, obstructive sleep apnea, and drug or alcohol induced hypertension before referral to RDN.”
> “The primary clinicians must coordinate management of the patient for a minimum of six months before referral for RDN, during which the patient had at least three encounters, with no more than two of the three encounters being virtual.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.2.2.1.8-4"></a>

###### CMS assessment of the evidence

> “We agree that while the evidence for RDN is promising, it does not yet satisfy the reasonable and necessary standard required for coverage under Section 1862(a)(1)(A) of the Social Security Act.”
> “In patients with resistant HTN, findings differed between the two On Med trials. In TRIO, uRDN reduced daytime ASBP statistically, but not meaningfully, more than the sham procedure at 2 months but not at 6 months.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.2.2.1.8-5"></a>

###### Place of renal denervation in resistant hypertension: 2025 AHA/ACC guideline

> “COR 1: All patients with hypertension who are being considered for RDN should be evaluated by a multidisciplinary team with expertise in resistant hypertension and RDN.”
> “While some trials showed a small but significant reduction in 24-hour ambulatory SBP by 3 to 5 mm Hg over the sham arm,”
> “RDN should not be considered as a curative therapy for hypertension or full replacement for antihypertensive drugs.”
> “Given the modest BP-lowering effects of RDN over the sham arm or addition of spironolactone, RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”
> “Only 60% to 70% of patients undergoing RDN experienced a meaningful reduction in ambulatory SBP of at least 5 mm Hg in clinical trials.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.8-6"></a>

###### Patient selection for renal denervation: 2025 AHA/ACC guideline

> “Patients with stage 2 hypertension (with both office SBP ≥140 mm Hg and office DBP ≥90 mm Hg) in whom BP is not at goal despite taking ≥4 antihypertensive medications at optimal dosages (ACEi/ARB +CCB +thiazide-type diuretics, and MRA)”
> “Patients with stage 2 hypertension (with both office SBP ≥140 mm Hg and office DBP ≥90 mm Hg) who are unable to take antihypertensive medications at the optimal dosages or additional medications”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.8-7"></a>

###### Renal denervation recommendation and limitations: 2024 ESC guideline

> “Based on the available evidence, renal denervation may be considered for patients who have uncontrolled, true resistant hypertension with a three-drug combination and who express a preference to undergo renal denervation.”
> “meta-analyses report placebo-corrected systolic BP lowering of approximately 6 mmHg on office BP assessment and 4 mmHg on 24 h ABPM”
> “Because of the lack of outcomes trials, renal denervation cannot reach the Class I indication threshold set by this task force.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.8-8"></a>

###### Renal denervation as an additive or alternative option: 2023 ESH guideline

> “Endovascular RDN with radiofrequency energy or high frequency unfocused ultrasound energy represents a treatment option, that is additive or alternative to increasing medication in patients with uncontrolled resistant hypertension confirmed by ABPM after excluding secondary causes of hypertension”
> “To date, no prospective multicenter, blinded, randomized, prospective outcome trial exists for RDN.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.8-9"></a>

###### Ultrasound renal denervation in resistant hypertension: RADIANCE-HTN TRIO trial

> “Eligible patients were switched to a once daily, fixed-dose, single-pill combination of a calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic.”
> “Between March 11, 2016, and March 13, 2020, 989 participants were enrolled and 136 were randomly assigned to renal denervation (n=69) or a sham procedure (n=67).”
> “Renal denervation reduced daytime ambulatory systolic blood pressure more than the sham procedure (-8·0 mm Hg [IQR -16·4 to 0·0] vs -3·0 mm Hg [-10·3 to 1·8]; median between-group difference -4·5 mm Hg [95% CI -8·5 to -0·3]; adjusted p=0·022)”

Source: [Azizi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34010611/)

<a id="topic-2.2.2.1.8-10"></a>

###### Ultrasound renal denervation without medications: RADIANCE II trial

> “Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001)”
> “No major adverse events were reported in either group.”

Source: [Azizi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975904/)

<a id="topic-2.2.2.1.8-11"></a>

###### Radiofrequency renal denervation with medications at 6 months: SPYRAL HTN-ON MED trial

> “The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12).”
> “RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015).”

Source: [Kandzari et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37914510/)

<a id="topic-2.2.2.1.8-12"></a>

###### Radiofrequency renal denervation with medications at 24 months: SPYRAL HTN-ON MED trial

> “At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.”
> “Clinically adverse events were rare, with no instances of renal artery stenosis through 24 months.”

Source: [Kandzari et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244969/)

<a id="topic-2.2.2.1.8-13"></a>

###### Radiofrequency renal denervation with medications at 36 months: SPYRAL HTN-ON MED pilot cohort

> “At 36 months, the ambulatory systolic blood pressure reduction was -18·7 mm Hg (SD 12·4) for the renal denervation group (n=30) and -8·6 mm Hg (14·6) for the sham control group (n=32; adjusted treatment difference -10·0 mm Hg, 95% CI -16·6 to -3·3; p=0·0039).”

Source: [Mahfoud et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35390320/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

- Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
- Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
- Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
- Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
- Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm); [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/); [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/); [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Chang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679429/); [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/); [Tajeu et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5215087/)

<a id="topic-2.2.2.1.9-2"></a>

###### Blood pressure control: NHANES August 2021 to August 2023

> “About one-fifth of adults with hypertension had their blood pressure controlled (20.7%) to less than 130/80 mm Hg.”
> “No significant change was seen between 2017–March 2020 and August 2021–August 2023 in the prevalence of hypertension awareness (60.2% compared with 59.2%), treatment (50.3% and 51.2%), or control (22.2% and 20.7%) among adults with hypertension (Figure 5, Table 5).”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.2.1.9-3"></a>

###### Blood pressure control: trends from 1999 to 2018

> “the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.”

Source: [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/)

<a id="topic-2.2.2.1.9-4"></a>

###### Blood pressure control and barriers to treatment: ICER assessment

> “Although decreasing blood pressure has been associated with improved outcomes, more than 70% of adults with hypertension continue to have a blood pressure above goal”
> “Clinical inertia, pill burden, additive copays for multiple medications, variable tolerance for side effects, and a lack of awareness of the importance of treating hypertension can make treatment challenging.”
> “one survey of US adults showed that 31% were non-adherent to medications”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-5"></a>

###### Underuse of mineralocorticoid receptor antagonists in apparent treatment-resistant hypertension

> “Among those with aTRH, 84.3% were on ACE inhibitors/ARBs, 72.1% on thiazide diuretics, 55.4% on calcium channel blockers, 32.3% on a loop diuretic and 8.3% on mineralocorticoid receptor antagonists (MRA).”
> “Among adults with aTRH, utilization of MRAs increased over time from 6.3% in 2003–2004 to 13.3% in 2017–2020.”
> “less than 1 in 5 adults with aTRH were prescribed an MRA despite high quality evidence supporting its use.”
> “Limited adaption could be related to the above issues or concerns specific to MRA use such as hyperkalemia, the need for routine monitoring of labs or concerns about renal dysfunction.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.2.1.9-6"></a>

###### Underuse of aldosterone-targeted therapy: lorundrostat phase 3 trial report

> “However, aldosterone-targeted antihypertensive medication is underused worldwide in the treatment of hypertension.”
> “However, MRAs are underused due to safety concerns with hyperkalemia and, in the case of spironolactone, chemotype-specific androgenic effects.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.1.9-7"></a>

###### Primary aldosteronism testing and mineralocorticoid receptor antagonist initiation

> “4277 (1.6%) patients who were tested for primary aldosteronism were identified.”
> “Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

<a id="topic-2.2.2.1.9-8"></a>

###### Spironolactone and eplerenone intolerance and efficacy: guideline

> “Nevertheless, 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone due to hyperkalemia or antiandrogenic side effects.”
> “Eplerenone, a more selective steroidal MRA that avoids the antiandrogenic side effects but may cause hyperkalemia, is a potential alternative to spironolactone, but RCTs have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily when compared with placebo, and effective treatment may require higher dosages.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-9"></a>

###### Hyperkalemia and gynecomastia with mineralocorticoid receptor antagonists

> “However, use of MRA medications is often limited by side effects, most prominently hyperkalemia and gynecomastia.”
> “In observational studies evaluating treatment for hypertension with spironolactone, gynecomastia rates ranged between 3.9 to 6%”
> “For people with apparent treatment-resistant hypertension who are already taking three or more antihypertensive medications and are not at their goal blood pressure, fourth-line options may be limited by side effects such as hyperkalemia and gynecomastia.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “MRAs are known to be effective in lowering BP; however, they have demonstrated side effects that have limited their use.”
> “Specifically, spironolactone, the most commonly prescribed MRA, is known for inducing hyperkalemia as well as gynecomastia in men and fertility issues in women.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.1.9-10"></a>

###### Clinician reluctance to start spironolactone: patient and clinician input to ICER

> “Additionally, patient groups mentioned that clinicians are often reluctant to start a fourth-line medication like spironolactone because of potential side effects”
> “For such individuals, mineralocorticoid receptor antagonists such as spironolactone are the preferred option; however, spironolactone may be difficult to take due to side effects, particularly for men.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-11"></a>

###### Aldosterone synthase inhibitors: hyperkalemia with baxdrostat

> “In the long-term extension of the BaxHTN trial, with safety data to 54 weeks, hyperkalemia led to treatment discontinuation in 5.7% of those in the pooled baxdrostat arm (1 mg and 2 mg),”
> “serum potassium levels greater than 6 mmol/L were reported in 9.5% of those in the pooled baxdrostat arm, and 0.8% of those in the placebo arm.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-12"></a>

###### Other fourth-line and add-on options: efficacy and tolerability

> “While there are alternative antihypertensive medications beyond MRAs, many of the other classes of agents (e.g., beta-blockers, alpha blockers, central sympatholytic drugs) tend to be less efficacious and less well-tolerated.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Aprocitentan has not been directly compared with spironolactone in the treatment of resistant hypertension and edema/fluid retention occurred in 9% at 12.5 mg (FDA–approved dose) versus 18% at 25 mg (unapproved dose) and 2% with placebo”
> “Given the modest BP-lowering effects of RDN over the sham arm or addition of spironolactone, RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-13"></a>

###### Medication nonadherence: insured US adults, 2015

> “We included 23.8 million hypertensive adults who filled 265.8 million prescriptions for antihypertensive medications.”
> “The overall weighted national nonadherence rate was 31.0%, with greater nonadherence among women versus men, younger versus older adults (aged 18-34 years, 58.1%; aged 65-74 years, 24.4%), fixed-dose combination medication nonusers (31.2%) versus users (29.4%), and by pharmacy outlet type (retail only, 30.7%; any mail order, 19.8%).”

Source: [Chang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679429/)

<a id="topic-2.2.2.1.9-14"></a>

###### Medication nonadherence: apparent treatment-resistant hypertension

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “By using a random effects model, the pooled prevalence of nonadherence was 31.2%”
> “with nonadherence rates ranging from 3.3 to 86.1%.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

<a id="topic-2.2.2.1.9-15"></a>

###### Discontinuation and low adherence after treatment initiation: Medicare beneficiaries

> “Between 2007 and 2012, 41,135 Medicare beneficiaries in the 5% sample initiated antihypertensive medication.”
> “Discontinuation was stable over the study period (21.0% in 2007 and 21.3% in 2012; p-trend=0.451).”
> “Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (p-trend<0.001).”

Source: [Tajeu et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5215087/)

<a id="topic-2.2.2.1.9-16"></a>

###### Therapeutic inertia

> “We also heard that there is clinical inertia when managing blood pressure and that it often takes three to six months to adjust or add a blood pressure medication, even in people with uncontrolled hypertension.”
> “We also heard that clinical inertia could result in suboptimal treatment of hypertension.”
> “For example, people living with hypertension told us that they had systolic blood pressure readings above 140 mm Hg at appointments, but their clinicians either did not address the reading and intensify therapy or told them that they did not need additional therapy.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Resistant hypertension is more common in Black populations, which may be related to adverse social factors, including living in a professional shortage area or disadvantaged neighborhood and clinical inertia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-17"></a>

###### Insurance coverage barriers

> “We heard that insurance coverage barriers, such as prior authorization and step therapy, can place a high burden on patients and can cause people to abandon treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

- Guideline sequence: The 2025 AHA/ACC guideline starts drug treatment of resistant hypertension with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic, then adds spironolactone (25 to 50 mg/day) as the fourth drug. Amiloride (10 to 20 mg) is the alternative when spironolactone or eplerenone is not tolerated, followed by beta-blockers, alpha blockers, central sympatholytic drugs, direct vasodilators, or aprocitentan. Renal denervation is reserved for adults with intolerable side effects to optimal drug regimens. ICER summarizes the guideline as recommending referral to a specialist for a known or suspected secondary cause or when blood pressure remains uncontrolled after more than 6 months of treatment.
- Anticipated use: Mineralys submitted the NDA for the treatment of hypertension in combination with other antihypertensive drugs, the same wording as the first part of the BAXFENDY (baxdrostat) indication, which adds adults not adequately controlled on other agents. Mineralys describes its target as third-line or later treatment, with resistant hypertension as the initial segment and a “beachhead at fourth line”. Manufacturers told ICER that they view aldosterone synthase inhibitors as appropriate for third- or fourth-line therapy regardless of whether a third first-line agent had been tried.
- ICER populations and clinical input: ICER assessed three populations: resistant hypertension not at goal; blood pressure above goal on two drugs with intolerance of a third first-line agent; and blood pressure above goal on two drugs without a trial of a third first-line agent. ICER consulted five clinical experts (two internists, two cardiologists, one nephrologist), who identified mineralocorticoid receptor antagonists such as spironolactone as the preferred option for people who remain uncontrolled despite regular medication use.
- Care setting: Lorundrostat is orally administered. Mineralys estimates about 60,000 physicians write half of the third-line or later prescriptions, with a 60/40 split between primary care and specialists, most of whom are cardiologists. The guideline assigns routine and complex hypertension care to primary care physicians and cardiologists, and complex care involving secondary causes or resistant hypertension to nephrologists, endocrinologists, and hypertension specialists.

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm); [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.2.2.2-2"></a>

###### Guideline treatment sequence for resistant hypertension

> “Antihypertensive drug therapy should start with a combination of an ACEi or ARB, a CCB, and a diuretic.”
> “RCTs have shown that addition of spironolactone (25-50 mg/day) as the fourth drug reduced home and 24-hour SBP by 6.6 to 8.7 mm Hg when compared with placebo in patients with resistant hypertension and eGFR ≥45 mL/min/1.73 m2”
> “When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10-20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension.”
> “Other alternative fourth- and fifth-line drug therapies include BBs, alpha blockers, central sympatholytic drugs, and direct vasodilators.”
> “RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.2-3"></a>

###### Guideline treatment sequence and specialist referral: ICER summary of the 2025 guideline

> “For resistant hypertension, which is defined as blood pressure above goal despite use of 3 antihypertensive medications with complementary mechanisms of action (including a diuretic) or blood pressure at goal on 4 or more antihypertensive medications, guideline recommendations include screening for secondary causes of hypertension, maximizing diuretic therapy, and adding spironolactone or eplerenone.”
> “If an additional agent is still needed, it is recommended to add agents with a different mechanism of action (e.g., beta-blocker, nondihydropyridine calcium channel blockers, vasodilators, dual endothelin-receptor antagonists).”
> “Finally, referral to a specialist is recommended for a known or suspected secondary cause(s) of hypertension, or if blood pressure remains uncontrolled after more than 6 months of treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-4"></a>

###### Proposed indication: use with other antihypertensive drugs

> “Based on the positive results from our pivotal program, we submitted an NDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”
> “Launch-HTN evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to participants’ existing, prescribed background treatment of two to five antihypertensive medications.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.2-5"></a>

###### Labeled place of the first aldosterone synthase inhibitor

> “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.2.2.2-6"></a>

###### Manufacturer positioning: third-line or later use

> “We believe the Launch-HTN and Advance-HTN trial results demonstrate the opportunity for lorundrostat in third-line or later treatment of patients with hypertension.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “As it relates to some of the dialogues that we have had with payers, we continue to feel bullish as it relates to access, particularly where we have targeted lorundrostat use. That is that third line or later. We think resistant is the natural opening space, and with experience, both from a physician standpoint and demand growing into the third-line usage.”
> “I can tell you, as Eric alluded to and I did in my prior comments, that based on the research we have done with payers right now, the value proposition of lorundrostat certainly resonates fourth line, with some payers even third line. I think it is going to be, as I noted, a beachhead at fourth line.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.2.2.2-7"></a>

###### Manufacturer positioning reported by ICER

> “Manufacturers suggested that they viewed aldosterone synthase inhibitors as appropriate for either third- or fourth-line therapy for patients with high blood pressure who are not at goal, regardless of whether patients had trialed a third first-line agent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-8"></a>

###### ICER assessment populations

> “We evaluated the net health benefits of baxdrostat and lorundrostat in three populations: (1) resistant hypertension not at goal; (2) blood pressure above goal while on two antihypertensive medications and did not tolerate a third first-line agent; and (3) blood pressure above goal while on two antihypertensive medications and who have not been treated with a third first-line agent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-9"></a>

###### Clinical expert views reported by ICER

> “We spoke with five clinical experts with expertise in treating patients with hypertension, including two internists, two cardiologists, and one nephrologist.”
> “Clinical experts emphasized that single pill combinations can help increase adherence to medications, but that some individuals with hypertension remain uncontrolled or have resistant hypertension even when they are taking medications regularly.”
> “For such individuals, mineralocorticoid receptor antagonists such as spironolactone are the preferred option; however, spironolactone may be difficult to take due to side effects, particularly for men.”
> “Finally, we heard that chronic kidney disease can complicate treatment for hypertension, as each of the three first-line therapies has limitations in this population”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-10"></a>

###### Care setting: prescribers targeted by the manufacturer

> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”
> “It is about a 60/40 split, primary care/specialty, the bulk of the specialty being cardiologists.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

> “The trial was designed to evaluate lorundrostat in a uHTN or rHTN population at the highest risk, which would normally be treated by a specialist, given the severity of their condition.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

###### Care setting: roles of the hypertension care team

| Team member | Role |
| --- | --- |
| “Primary care physician/cardiologist, physician assistant or associate/nurse practitioner/advanced practice nurse” | “Routine and complex hypertension care, managing primary care issues” |
| “Nephrologist, endocrinologist, hypertension specialist” | “Management of complex hypertension care, especially due to secondary causes, and/or resistant hypertension” |
| “Clinical Pharmacist” | “Comprehensive medication management, identification of medication-related interactions, and educating patients on their medication regimen” |

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary

- Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
- Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
- Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat); [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/); [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/); [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.3-2"></a>

###### Lorundrostat subgroups in Launch-HTN: age, sex, race, body mass index, and number of background drugs

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications.”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.”
> “A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.3-3"></a>

###### Lorundrostat subgroups in Launch-HTN: ICER assessment

> “In the Launch-HTN study, treatment effects between lorundrostat and placebo at week six were consistent across the subgroups of age, sex, race, baseline SBP, BMI, waist-to-hip ratio, and eGFR”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-4"></a>

###### Lorundrostat by chronic kidney disease status in Launch-HTN

> “CKD was defined as eGFR <60mL/min/1.73m2 or UACR ≥30mg/g.”
> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table).”
> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.2.2.3-5"></a>

###### Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12

| CKD stage | Lorundrostat 50 mg participants | Placebo-adjusted AOSBP change, mm Hg (95% CI) | Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg |
| --- | --- | --- | --- |
| No CKD | “N=406” | “-12.2 (-17.1, -7.3)” | “48.0” |
| Stage 1 | “N=58” | “-10.6 (-18.6, -2.6)” | “50.6” |
| Stage 2 | “N=31” | “-7.6 (-16.5, 1.4)” | “28.4” |
| Stage 3 | “N=38” | “-10.1 (-21.1, 1.0)” | “47.0” |

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.2.2.3-6"></a>

###### Lorundrostat by obesity and diuretic use in Target-HTN

> “Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.”
> “Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.”
> “Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.”
> “Blood pressure decreases were attenuated among participants not taking a diuretic”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.2.2.3-7"></a>

###### Lorundrostat by plasma renin status in Target-HTN

> “Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1.”
> “Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.2.2.3-8"></a>

###### Lorundrostat in obstructive sleep apnea with obesity

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “A clinically meaningful reduction in office SBP in adults with moderate-to-severe OSA and hypertension was seen, with similar magnitude compared with prior pivotal lorundrostat treatment trials in patients with uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.3-9"></a>

###### Number of background antihypertensive drugs: class evidence used by ICER

> “First, subgroup analyses from baxdrostat and lorundrostat studies showed similar treatment effects among patients taking two versus three or more antihypertensive medications at baseline.”
> “Second, a meta-analysis of mineralocorticoid antagonists found no differential blood pressure lowering between resistant and non-resistant hypertension”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-10"></a>

###### Baxdrostat subgroups

> “In the BaxHTN and Bax24 studies, treatment effects between baxdrostat and placebo on SBP at week 12 were consistent across all prespecified subgroups (age, sex, race, ethnicity, geographic region, baseline SBP, eGFR, and BMI).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-11"></a>

###### Spironolactone response by plasma renin

> “Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

> “Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.3-12"></a>

###### Race and ethnicity: clinician input to ICER

> “we heard that although there may be differences in treatment effects by race or ethnicity, those differences are small and not likely to be clinically significant.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-13"></a>

###### Advanced chronic kidney disease excluded from pivotal trials

> “The pivotal trials for baxdrostat and lorundrostat excluded subgroups such as those with advanced chronic kidney disease.”
> “Ongoing studies may address whether ASIs are effective and safe in such subgroups.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary

- Team-based care: The 2025 AHA/ACC guideline describes multidisciplinary team-based care, including pharmacists, nurses, and community health workers, as effective in addressing barriers to blood pressure control. In a meta-analysis of 19 studies (5,993 participants), team-based care lowered systolic blood pressure at 12 months by 10.5 mm Hg with non-physician medication titration and 5.0 mm Hg with physician titration compared with usual care; the non-physician titration strategy was estimated at $4,400 per QALY gained over 10 years.
- Pharmacist management: In a cluster-randomized trial of 319 Black men recruited in 52 barbershops, pharmacist-led drug management reduced systolic blood pressure by 21.6 mm Hg more than the control approach at 6 months. A model estimated that 50% uptake of pharmacist prescribing would save $1.137 trillion and 30.2 million life years over 30 years.
- Home blood pressure monitoring and adherence: The guideline states that home blood pressure monitoring improves office blood pressure control when combined with other interventions, and lists dose consolidation, single-pill combinations, pharmacist education, home monitoring with feedback, shared decision-making, and medication synchronization and reminders as evidence-based adherence strategies.

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/); [Victor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6018053/); [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-2.2.2.4-2"></a>

###### Team-based care: guideline

> “Multidisciplinary team-based care is effective in assessing and addressing patient access to medications and other structural barriers to support individual patient needs and thereby reduce barriers to achieving hypertension control. Team members may include physicians, pharmacists, nurse practitioners, nurses, physician assistants/associates, dieticians, community health workers, and other health care professionals.”
> “RCTs and meta-analyses of RCTs of team-based hypertension care involving nurse or pharmacist intervention demonstrated reductions in SBP and DBP and/or greater achievement of BP goals when compared with usual care.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-3"></a>

###### Team-based care: meta-analysis and cost-effectiveness

> “Among 19 studies comprising 5,993 participants, the 12-month SBP change vs. usual care was −5.0 (95% confidence interval: −7.9 to −2.2) mmHg for TBC with physician titration and −10.5 (−16.2 to −4.8) mmHg for TBC with non-physician titration.”
> “Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.”

Source: [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/)

<a id="topic-2.2.2.4-4"></a>

###### Pharmacist-led management: barbershop trial in Black men

> “We enrolled a cohort of 319 black male patrons with systolic blood pressure of 140 mm Hg or more from 52 black-owned barbershops (nontraditional health care setting) in a cluster-randomized trial in which barbershops were assigned to a pharmacist-led intervention (in which barbers encouraged meetings in barbershops with specialty-trained pharmacists who prescribed drug therapy under a collaborative practice agreement with the participants’ doctors) or to an active control approach (in which barbers encouraged lifestyle modification and doctor appointments).”
> “At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).”

Source: [Victor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6018053/)

<a id="topic-2.2.2.4-5"></a>

###### Pharmacist prescribing: US cost-effectiveness

> “In this simulated cost-effectiveness analysis of a 5-state Markov model, 50% uptake of a pharmacist-prescribing intervention to improve blood pressure control was associated with a $1.137 trillion in cost savings and could save an estimated 30.2 million life years over 30 years.”

Source: [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-2.2.2.4-6"></a>

###### Home blood pressure monitoring

> “Home blood pressure monitoring combined with frequent interactions with multidisciplinary team members using standardized measurement and treatment protocols and home measurement protocols is an important integrated tool to improve rates of blood pressure control.”
> “Among adults taking antihypertensive medication, compared with usual care, HBPM use improves office BP control when used in conjunction with other interventions to lower BP.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-7"></a>

###### Adherence interventions

> “Dose consolidation”
> “Single pill combination rather than separate pills”
> “Education/coaching by pharmacists and other health professionals”
> “Electronic/home blood pressure monitoring and feedback”
> “Integration of patient preferences and values/shared decision-making into management plan”
> “Medication synchronization and reminder aids”
> “RCTs, systematic reviews, and meta-analyses provide evidence that the following interventions can improve adherence: medication reminder aids (eg, text, telephone, smartphone apps); patient education and self-management programs”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-8"></a>

###### Patient-reported needs: dietary counseling and peer education

> “others report that they did not receive dietary counseling and/or referrals to resources such as a registered dietitian or nutritionist to help manage the disease.”
> “Finally, we heard that peer education is important, as peer-to-peer interactions can reinforce physician messages on hypertension treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Shimbo et al. (2020)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000803)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Benefit per unit of blood pressure reduction: An individual participant-level meta-analysis of 48 trials found that each 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events by about 10%, with reductions of 13% for stroke, 13% for heart failure, 8% for ischemic heart disease, and 5% for cardiovascular death, irrespective of prior cardiovascular disease. A meta-analysis of 123 studies (613,815 participants) found that each 10 mm Hg reduction lowered major cardiovascular events (relative risk 0.80), coronary heart disease (0.83), stroke (0.73), heart failure (0.72), and all-cause mortality (0.87), with no significant effect on renal failure. FDA guidance attributes these benefits largely to the decrease in blood pressure itself across drug classes.
- Lorundrostat: In Launch-HTN, lorundrostat 50 mg lowered office systolic blood pressure by 9.1 mm Hg more than placebo at week 6. No trial of lorundrostat or baxdrostat reporting cardiovascular, kidney, or mortality outcomes was identified; the placebo-controlled Launch-HTN comparison lasted 12 weeks.
- Blood pressure as a surrogate: ICER states that blood pressure is a surrogate marker, that not all blood pressure drugs have the same effect on major adverse cardiovascular events and their effects on mortality are inconsistent, and that longer-term data are needed to determine the effect of aldosterone synthase inhibitors on patient-important outcomes. A review of FDA surrogate endpoints found 10 meta-analyses with inconsistent evidence on the strength of association between blood pressure reductions and cardiovascular outcomes and all-cause mortality. The Explore-OSA investigators state that a longer-term cardiovascular outcomes trial of lorundrostat should be considered.

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/); [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/); [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Wallach et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11036312/); [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.7-2"></a>

###### Cardiovascular benefit per 5 mm Hg reduction in systolic blood pressure

> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”
> “On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-2.2.2.7-3"></a>

###### Cardiovascular benefit per 10 mm Hg reduction in systolic blood pressure

> “We identified 123 studies with 613,815 participants for the tabular meta-analysis.”
> “Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).”
> “However, the effect on renal failure was not significant (0·95, 0·84-1·07).”
> “There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.”

Source: [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/)

<a id="topic-2.2.2.7-4"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit: FDA guidance

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-2.2.2.7-5"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit: ICER background

> “a meta-analysis of nearly 50 randomized controlled trials demonstrated that a 5 mm Hg decrease in systolic blood pressure was associated with a roughly 10% decrease in major adverse cardiovascular events (MACE).”
> “However, blood pressure is a surrogate marker and not all blood pressure drugs have the same effect on MACE, and their effects on mortality are also inconsistent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.7-6"></a>

###### Blood pressure as a surrogate marker: strength of evidence

> “Of 5541 records screened, 10 meta-analyses offered inconsistent evidence on the strength of association between reductions in systolic or diastolic blood pressure and improvements in cardiovascular outcomes and all-cause mortality (eTable 10 and eFigure 26 in Supplement 1).”

Source: [Wallach et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11036312/)

<a id="topic-2.2.2.7-7"></a>

###### Lorundrostat blood pressure effect in the phase 3 trial

> “For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).”
> “First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.7-8"></a>

###### Absence of outcome data for aldosterone synthase inhibitors

> “The pivotal trials for baxdrostat and lorundrostat measured short-term changes in systolic blood pressure, which is a surrogate endpoint.”
> “Although a reduction in blood pressure has been associated with an overall decrease in major adverse cardiovascular events (MACE) and progression of chronic kidney disease, not all drugs affect all components of MACE or decrease mortality.”
> “Additional, longer-term data for baxdrostat and lorundrostat are necessary to determine their impact on patient-important outcomes.”
> “Finally, we await the long-term extension study for lorundrostat, as there may be different effects, even for drugs within the same class.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Given the high prevalence of aldosterone dysregulation and its association with cardiometabolic disease in OSA, a longer-term CV outcomes trial of lorundrostat should be considered.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.7-9"></a>

###### Expected benefit of a new class: ICER

> “Thus, a new class of effective antihypertensive medications with a favorable side effect profile could help increase the number of patients with hypertension who reach their blood pressure goals and potentially see a decrease in cardiovascular or kidney events.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.7-10"></a>

###### Expected benefit as stated by the manufacturer

> “In a meta-analysis of 147 randomized trials, a 10 mmHg reduction in systolic BP or a 5 mmHg reduction in diastolic BP has been shown to reduce the risk of stroke by 41% and coronary heart disease by 22%.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.7-11"></a>

###### Blood pressure as a modifiable risk factor: guideline

> “High blood pressure is the most prevalent and modifiable risk factor for the development of cardiovascular diseases, including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
